

Señor

SUPERINTENDENTE DE INDUSTRIA Y COMERCIO

DIVISION DE NUEVAS CREACIONES

E. S. D.

Re P1-40 J'S. LLC.- Solicitud de Patente de Invención para
"COMPUESTOS PARA SENSIBILIZACIÓN DE TEJIDOS PARA
MUJERES, CON METODOS Y APARATO PARA LA LIBERACIÓN
DE ESTOS COMPUESTOS".- Clase A61m35/00 ó A61K 31/195.-
Expediente número 00-097.103.-

1 Me refiero a mi solicitud arriba nombrada de fecha 21 de Diciembre de 2000

2. Anexos me permito presentar a usted:

- (1) Copia autentica, debidamente certificada de la solicitud de patente presentada para el invento arriba nombrado respecto de la cual reclamo prioridad, a saber la solicitud estadinense número 09/469 959 de 21 de Diciembre de 1999, junto con su traducción correspondiente a las legalizaciones y reivindicaciones de dicho documento;
- (2) Copia autentica, debidamente certificada de la solicitud de patente presentada para el invento arriba nombrado respecto de la cual reclamo prioridad, a saber la solicitud estadinense número 09/520 110 de 7 de Marzo de 2000, junto con su traducción correspondiente a las legalizaciones y reivindicaciones de dicho documento; y
- (3) Copia debidamente autenticada por el Notario Sexto del Circulo de Bogotá, de los documentos que acreditan la calidad de Traductor Oficial de la señora Angela Alexandra Pulecio Mayorga quien elaboró la traducción de la legalizaciones de las solicitudes estadinenses número 09/469 959 y 09/520 110 de 21 de Diciembre de 1999 y 7 de Marzo de 2000 respectivamente.

31

3. Ruego a usted tomar atenta nota de lo anterior y proceder de conformidad.

Señor Superintendente,

JOSE ANTONIO LLOREDA

T P 10.784

Código 231


35
32



**EL SUSCRITO JEFE DEL AREA DE
LEGALIZACIONES DEL MINISTERIO DE
RELACIONES EXTERIORES**

CERTIFICA

Que revisados los registros que se llevan en la oficina de Legalizaciones aparece la firma del señora **ANGELA ALEXANDRA PULECIO MAYORGA**, como traductor e intérprete oficial para los idiomas **INGLES- ESPAÑOL, INGLES** según resolución 0177 del 11 de Marzo de 1997, del Ministerio de Justicia.

Dada en Santa Fe de Bogotá, D.C., a los veinte y dos (22) días de Diciembre de 2000


CARLOS GUILLERMO DIAZ BUTRAGO
Jefe Area de Legalizaciones



REPUBLICA DE COLOMBIA
TRIBUNAL SUPERIOR DEL DISTRITO JUDICIAL
DE SANTA FE DE BOGOTA D.C.
SALA GENERAL

ACUERDO Nro. 048

DILIGENCIA DE POSESION DE ANGELA ALEXANDRA PULECIO MAYORGA COMO
TRADUCTOR E INTERPRETE OFICIAL DE LOS IDIOMAS:
INGLES - ESPANOL - ESPANOL - INGLES


EN SANTA FE DE BOGOTA D.C. A LOS SEIS (6) DIAS DEL MES DE MAYO DE
MIL NOVECIENTOS NOVENTA Y SIETE (1997) COMPARECIO AL DESPACHO DEL
SEÑOR PRESIDENTE DEL TRIBUNAL SUPERIOR DE SANTA FE DE BOGOTA, ANGELA
ALEXANDRA PULECIO MAYORGA IDENTIFICADA CON LA CEDULA DE CIUDADANIA
No. 38.872.323 EXPEDIDA EN BUGA CON EL FIN DE TOMAR POSESION DEL
CARGO DE TRADUCTOR E INTERPRETE OFICIAL PARA EL CUAL FUE ADMITIDA
MEDIANTE RESOLUCION NRO 0177 DE MARZO ONCE (11) DE MIL NOVECIENTOS
NOVENTA Y SIETE (1997), EMANADA DEL MINISTERIO DE JUSTICIA Y DEL
DERECHO.


PARA TAL EFECTO, EL SEÑOR PRESIDENTE DE LA CORPORACION, LE RECIBIO
EL JURAMENTO DE RIGOR POR CUYA GRAVEDAD PROMETIO CUMPLIR BIEN Y
FIELMENTE CON SUS DEBERES.

SE FIRMA POR QUIENES EN LA DILIGENCIA INTERVINIERON PARA
CONSTAR QUE LA COPIA QUE SE LE EXPIDE A LA INTERVENIDA, COINCIDE
SU CALIDAD DE TRADUCTOR E INTERPRETE OFICIAL.

SE FIRMÓ EN SANTA FE DE BOGOTA
COMO NOTARIO SEXTO DE
SANTA FE DE BOGOTA
HAGO CONSTAR
QUE LA FOTOCOPIA QUE SE LE EXPIDE
COINCIDE CON LA FOTOCOPIA
DEL ORIGINAL QUE SE LE EXPIDE
A LA INTERVENIDA
FELIX A. BOTERO MEDINA
NOTARIO


RAMIRO TORRES LOZANO
PRESIDENTE


ANGELA ALEXANDRA PULECIO MAYORGA
POSESIONADA


MARIA INES RODRIGUEZ TORRES
SECRETARIA

NOTARIA 36-SANTA FE DE BOGOTA
Como Notaria 36 de esta Circulo hago
constar que esta copia coincide con el
documento original presentado para
su autenticación
12 FEB 2001
MARIO TORRES VALDERRAMA
NOTARIO TREINTA Y SEIS



MINISTERIO DE JUSTICIA Y DEL DERECHO

RESOLUCION NUMERO

0177

DE 19

11 MAR. 1997

Por la cual se expide una licencia para ejercer funciones de Traductor e Intérprete Oficial

LA SECRETARIA GENERAL DEL MINISTERIO DE JUSTICIA Y DEL DERECHO

en ejercicio de la facultad conferida por la Resolución 0601 del 30 de marzo de 1995, y

CONSIDERANDO:

Que ANGELA ALEXANDRA PULECIO MAYORGA, identificada con la cédula de ciudadanía No 38 872 323 de Buga (Valle), solicita a este Ministerio le sea expedida licencia para ejercer funciones de Traductor e Intérprete oficial de conformidad con los Decretos 382 y 2257 de 1951


Que la peticionaria ha acompañado a su solicitud los siguientes documentos

a Fotocopia autenticada de la cédula de ciudadanía No 38 872 323 de Buga (Valle), en donde se establece la mayoría de edad

b Certificación expedida por el Jefe de la Oficina Jurídica del Ministerio de Educación Nacional, que acredita su idoneidad como traductor e Intérprete oficial en los idiomas INGLES-ESPAÑOL-ESPAÑOL-INGLES

c Tres declaraciones de personas que manifiestan que el peticionario tiene buena conducta

d Fotocopia autenticada del certificado judicial registrado bajo el No 38 872 323 expedido por el Departamento Administrativo de Seguridad donde certifica que ANGELA ALEXANDRA PULECIO MAYORGA no tiene asuntos pendientes con las autoridades judiciales o de policía



RESUELVE

ARTICULO PRIMERO: Expedir licencia a ANGELA ALEXANDRA PULECIO MAYORGA, identificada con la cédula de ciudadanía No 38 872 323 de Buga (Valle), para ejercer las funciones de Traductor e Intérprete Oficial en los idiomas INGLES- ESPAÑOL- ESPAÑOL-INGLES.

Hoja 2 de la Resolución "Por la cual se expide una licencia para ejercer funciones de Traductor e Intérprete Oficial a ANGELA ALEXANDRA PULECIO MAYORGA

ARTICULO SEGUNDO: Comunicar el texto de la Resolución a la Subsecretaria de Asuntos Administrativos del Ministerio de Relaciones Exteriores

ARTICULO TERCERO: La interesada deberá registrar su firma y sello ante la Oficina de Autenticaciones del Ministerio de Relaciones Exteriores, e inscribir su nombre ante el Tribunal Superior del Distrito Judicial correspondiente al territorio donde vaya a desempeñarse


ARTICULO CUARTO: La presente resolución rige a partir de la fecha de su expedición, y contra ella proceden los recursos de reposición y apelación los cuales deberán ser interpuestos dentro de los cinco días siguientes a su notificación

NOTIFIQUESE, COMUNIQUESE Y CUMPLASE
Dada en Santa Fe de Bogotá, D C a

11 MAR. 1997

[Firma manuscrita]
YOLANDA GOMEZ RESTREPO

[Firma manuscrita]
LAR/mmc



TRADUCCION OFICIAL NO. 006-2001
DE UN DOCUMENTO ESCRITO EN INGLES

ESTADOS UNIDOS DE AMÉRICA

**A TODOS AQUELLOS QUE LLEGAREN A LEER EL CONTENIDO DE ESTE
DOCUMENTO**

DEPARTAMENTO DE COMERCIO DE LOS ESTADOS UNIDOS

Oficina de Marcas y Patentes de los Estados Unidos

Enero 3 de 2001

Mediante este documento se certifica que anexo al presente se encuentra una fiel copia de los Registros de la Oficina de Marcas y Patentes de los Estados Unidos de América correspondientes a la solicitud de patente abajo identificada la cual cumplió con los requerimientos exigidos para el otorgamiento de una fecha de presentacion de conformidad con lo dispuesto en la Seccion 35 USC 111

Número de Solicitud: 09/469.959

Fecha de Presentación: Diciembre 21 de 1999

Por autoridad del

COMISIONADO DE MARCAS Y PATENTES

Angela Pulido
ANGELA A. PULECIO MORA
Traductor e Intérprete
Resol. No. 011 661/97 L. H. Justicia

40
37

P.R. GRANT

Funcionario Encargado de Certificaciones (Firma y Sello)

=====

Sello JC553 U S PTO (Oficina de Marcas y Patentes)

(Código de Barras)

12/21/99

Sello JC526 U S PTO (Oficina de Marcas y Patentes)

09/469959

(Codigo de Barras)

12/21/99

Expediente de Practicante No. Thompson-3

PATENTE

EN LA OFICINA DE MARCAS Y PATENTES DE ESTADOS UNIDOS

Solicitud de Patente

Comisionado Asistente para Patentes

Washington D C 20231

Angela A. Pulecio
ANGELA A. PULECIO MAYORGA
Traductor e Intérprete
Resol. No. 01/7 GCI/97 MINJUSCIB

TRANSMISION DE NUEVA SOLICITUD

Por el presente se transmite para presentación la solicitud de patente del (los)

inventor(es) *THOMPSON, R.J.*

Advertencia: La sección 37 CFR 1 41(a)(1) señala

(a) Las patentes son solicitadas a nombre o nombres de su actual o actuales inventor(es)

(1) La titularidad de invención de una solicitud no provisional es aquella titularidad de invención establecida en el juramento o declaración como se establece en 1 63, a excepción de lo previsto por 1 53(d)(4) y 1 63(d) Si un juramento o declaración de conformidad con 1 63 no es presentado mientras esté pendiente una solicitud no provisional, la titularidad de invención será aquella establecida en los documentos de solicitud presentados de conformidad con 1 53(b) a menos que se presente una petición bajo este parrafo acompañado por la tasa establecida en 1 17(i) en donde se suministre o cambie el nombre o nombres del inventor o inventores

Para (Titulo) **Mecanismo de Sensibilización del clitoris mediante el uso de un compuesto de Mentol y L-Arginina**

CERTIFICACION BAJO LA SECCION 37 CFR 1.10*

(El número de etiqueta del Correo Expreso es obligatorio)

(La certificación del Correo Expreso es opcional)

Angela A. Pulido
ANGELA A. PULIDO
Traductor e i.
Resol. No 0177 6/1/91 Industria

Por el presente certifico que esta Transmisión de Nueva Solicitud y los documentos referidos como los anexos de aquella están siendo depositados en el Servicio Postal de los Estados Unidos este 22 de Diciembre de 1999 en un sobre como "Oficina Postal de Correo Expreso para el destinatario", Numero de Envio EE83135195305, dirigido al Comisionado Asistente para Patentes, Washington D C 20231

AZ
39

(D N Halgrek

(escribir nombre de persona que envia documento)

(Firma)

(Firma de persona que envía documento)

Advertencia: Los procedimientos de Certificado de envío (primera clase) o transmisión de fax según la Sección 37 CFR 1.8 no pueden ser usados para obtener una fecha de envío o transmisión para esta correspondencia

Advertencia: Cada documento o tasa presentados por "Correo Expreso" deberá contener el número de la etiqueta de envío de "Correo Expreso" colocado antes del envío Sección 37 CFR 1.10(b)

"Teniendo en cuenta que la presentación de correspondencia bajo la Sección 1.10 que no tenga fijada la etiqueta de envío de Correo Expreso es una omisión que se puede evitar con el cuidado razonable las solicitudes de renuncia a este requerimiento no serán concedidas bajo petición" Aviso de Oct 24 de 1996 60 Reg Fed 56 439 a 56 442

1. Tipo de Solicitud

Esta solicitud consiste en un(a)

(indicar abajo un asunto aplicable)

 X Original (no provisional)

 Diseño

 Planta

Angela A. Pulido
ANGELA A. PULIDO 11/1/1988
Traductor é l. 1
Resol No 01/7 661/51 l. II. Justicia

43
40

ADVERTENCIA: No usar esta transmisión para el cumplimiento en E U de una
Solicitud Internacional bajo la Sección 35 U.S.C 371(c)(4), a menos
que la Solicitud Internacional esté siendo presentada como una
solicitud de división, de continuacion o continuación en parte

ADVERTENCIA: No usar esta transmisión para la presentacion de una solicitud
provisional

NOTA Si se aplica alguno de los siguientes 3 puntos, complete y adjunte LAS
PAGINAS PARA UNA NUEVA TRANSMISION DE SOLICITUD DONDE
HAYA UN BENEFICIO DE REIVINDICACION DE UNA SOLICITUD
ESTADOUNIDENSE ANTERIOR y una NOTIFICACION EN LA SOLICITUD
MATRIZ DE LA PRESENTACION DE ESTA SOLICITUD DE
CONTINUACION

☐ De division

☐ Continuación

☒ Continuacion en parte (C-E-P)

- 2 Beneficio de una(s) Solicitud(es) Estadounidense(s) anterior(es) (35 U S C
1993(e), 120. o 121)
(EN BLANCO)

3. Documentos Anexos:

Charles J. Puleo
ANGELA A. PULEO, Esq.
Traductora y
Resol No 017 del 17 de la Justicia

A Se requiere para la fecha de presentación de la Solicitud bajo la Sección 37 CFR 1 53(b) (Regular) o 37 CFR 1 153 (Diseño)

15 Páginas de especificaciones

3 Páginas de reivindicaciones

1 Páginas de dibujos

ADVERTENCIA: NO enviar dibujos originales Al presentar una solicitud de patente se debe presentar una copia de alta calidad de los dibujos Los dibujos que son enviados a la Oficina deben encontrarse en un papel fuerte blanco liso y no brillante y deben cumplir con los estándares de acuerdo con 1 84 Si es necesario hacer correcciones a los dibujos, deberán hacerse sobre el original y luego deberá enviarse a la Oficina una copia de alta calidad del original corregido Solo se requiere de una copia Para comentarios en lo propuesto por aquella Sección 37 CFR 1 84, ver Aviso de Marzo 9, 1988 (1990 O G 57-62)

NOTA Indicios de identificación, si son suministrados, deberán incluir el número de solicitud o el título de la invención, el nombre del inventor, el número de expediente (si existe), y el número y teléfono de una persona para ser llamada en caso de que la Oficina no pueda ajustar los dibujos a la solicitud adecuada Esta información debe ser colocada en la parte trasera de la hoja del dibujo a una distancia mínima de 1 5 cm (5/8 pulgadas) hacia abajo desde la parte superior de la hoja " 37 CFR 1 84 (c))

Angela A. Puleo
ANGELA A. PULEO
Traductor e Int.
Resol. No. 017 del 17/05/97 Industria

45
42

42

X Informal

Paginas de declaración y poder de abogado

Otros

ANGELA A FULFORD, WMA
 Trajuct 1 & 2
 Resol. No 1061/01 Introduction

(EN BLANCO)

5. Declaración o juramento (incluye poder)

7

46
43

1 47, entonces se deberá presentar una copia de esa declaracion
acompañada de una copia de la decisión que le concedió el estado 1 47 o si
una persona que no ha firmado bajo la sección 1 47 se ha unido con
posterioridad en una solicitud anterior, entonces deberá presentarse una
copia de la declaración posterior firmada Ver 37 CFR Sección 1 63 (d)(1)-
(3)

NOTA Una declaración presentada para completar una solicitud deberá
encontrarse firmada identificar la especificación respecto de la cual se
dirige, identificar a cada inventor con su nombre completo incluyendo el
apellido y al menos un nombre, sin abreviación junto con cualquier otro
nombre o inicial, así como la residencia, dirección postal y país o
ciudadanía de cada inventor, y declarar si el inventor es único o conjunto
37 C F R Sección 1 63 (a)(1)-(4)

_____ Se anexa

Firmado por

(marcar todas las casillas aplicables)

_____ Inventor(es)

_____ Representante legal del inventor(es)

37 CFR 1 42 o 1 43

Angela A. Furi...
ANGELA A FURI...
Traductor e I...
Resol No 217 CEI...
...destino

47
44

____ Inventor conjunto o persona que demuestre una titularidad a nombre del inventor que se negó a firmar o que no pudo ser localizado

____ Esta es la petición requerida por 37 CFR 1 47 y la declaración requerida por 37 CFR 1 47 también se adjunta.
Ver punto 13 más abajo para la tasa.

X No se Anexa

NOTA *Donde la presentación sea en cumplimiento en los E U de una Solicitud Internacional o donde el cumplimiento de la solicitud Estadounidense contenga asuntos adicionales a la solicitud Internacional, la solicitud podrá ser tratada como una continuación o continuación en parte, según sea el caso mediante el uso de PAGINAS ADICIONALES PARA LA TRANSMISION DE UNA NUEVA SOLICITUD DONDE SE REIVINDIQUE EL BENEFICIO DE LA PRIORIDAD DE LA SOLICITUD ESTADOUNIDENSE.*

____ La solicitud es hecha por una persona autorizada según la Sección 37 CFR 1 41 (c) a nombre de *todos* los inventores antes mencionados

(La declaracion o juramento, junto con la sobretasa requerida por la Sección 37 CFR 1 16(e) pueden presentarse con posterioridad)

____ Demostracion de que la presentación fue autorizada
(no es necesario a menos que sea requerida 37 CFR 1 37 (d))

Handwritten signature: Angela A. Plummer
ANGELA A. PLUMMER, RBA
TRA. 1037 (d)
RESOL. 1037 (d) 1037 (d) 1037 (d)

48
45

6. **Declaración de Titularidad de Invención**

ADVERTENCIA: Si los inventores mencionados no son cada uno de los inventores de todas las reivindicaciones, deberá remitirse una explicación, incluyendo la titularidad de las varias reivindicaciones al momento en que fue hecha la última reivindicación

La titularidad de invención de todas las reivindicaciones en esta solicitud son

☒ **Iguales**

O

☐ **No son iguales** Se realizó una explicación, incluyendo la titularidad de las varias reivindicaciones al momento en que fue hecha la última reivindicación

☐ **Se presenta**

☐ **No se presenta.**

7. **Idioma**

NOTA Se puede presentar una solicitud en idioma diferente al inglés incluyendo un juramento o declaración firmado Se requiere presentar una traducción al inglés de la solicitud en otro idioma y la tasa de procesamiento de \$130 00 ordenado por 37 CFR 1 17(k), al momento de presentación de la solicitud o cuando la Oficina lo requiera. 37 CFR 1 52 (d)

☒ **Inglés**

☐ **Otro idioma**

Angela M. Pulido
ANGELA M. PULIDO, P.A.
Traductor U.S. Patent & Trademark Office
Resol. No 0177 del 11 de mayo del 2011

49
46

____ La traducción adjunta incluye una declaración de que la traducción es exacta 37 CFR 1 52(d)

8. Cesión

X Una cesión de la invención a 40J'S LLC

____ se anexa. También se anexa una ____ "CARATULA DE CESION (DOCUMENTO) QUE ACOMPAÑA LA NUEVA SOLICITUD DE PATENTE" o ____ FORMULARIO DE LA OMP 1595

X Se presentara próximamente

NOTA Si se presenta una cesión con una solicitud nueva, enviar dos cartas separadas una para la solicitud y otra para la cesión" Aviso de Mayo 4 1990 (1114 O G 77-78)

ADVERTENCIA: *Debe presentarse un nuevo "CERTIFICADO BAJO LA SECCION 37 CFR 3 73 (b)" debidamente firmado cuando se presenta por parte del cesionario una solicitud de continuación en parte Aviso de 30 de Abril de 1993 1150 O G 62-64*

9. Copia Certificada

(EN BLANCO)

10 Cálculo de Tasa (37 CFR 1 16)

A. X Solicitud Normal

Angela A. Pulecio
ANGELA A. PULECIO 11/11/16A
Traductor e Intérprete Oficial
Resol. No 0177 del/97 MinJusticia

80
47

REIVINDICACIONES SEGÚN PRESENTACION

Numero presentado	Número Extra	Tasa	Tarifa Básica
			37 CFR 1 16 (a)
			\$760 00
Total			
Reivindicaciones			
(37 CFR 1 16(c)) 11-20=	x	\$22 00	
Reivindicaciones			
Independientes			
(37 CFR 1 16 (b)) 2-3 =	x	\$82 00	
Reivindicaciones			
Dependientes			
Multiples			
Si hay(37 CFR 1 16(d))	+	\$270 00	

Angela A. Pulecio
ANGELA A. PULECIO MAYORGA
Traductor e intérprete oficial
Presol No 0177 CC/1121, Industria

54
48

- ☐ Se adjunta corrección cancelando reivindicaciones adicionales
- ☐ Se anexa corrección eliminando dependencias multiples
- ☐ No se pagarán en este momento tasas para reivindicaciones adicionales

NOTA Si las tasas por reivindicaciones no son pagadas al momento de la presentación deberán ser pagadas o de lo contrario las reivindicaciones serán canceladas por la corrección, antes de la expiración del periodo establecido para respuesta por la Oficina de marcas y Patentes en cualquier aviso de incumplimiento de tasas 37 CFR 1 16 (d)

Calculo de Tasa de Presentación \$760 00

B. Solicitud de Diseño

(EN BLANCO)

C. Solicitud de Planta

(EN BLANCO)

Angela A. Pulecio Mayrba
Trajuctor e Inscrito Oficial
Resol. No. 0177 del 15/11/2018

11 **Declaración de Pequeña Entidad**

 X Se presentara declaración(es) de que este documento es presentado por una pequeña entidad bajo la sección 37 CFR 1 9 y 1 27

(completar lo siguiente si es aplicable)

☐ La calidad de pequeña entidad fue reivindicada en una solicitud anterior

_____/_____, presentada en _____, de la cual se reivindica beneficio para esta solicitud bajo la

- Sección 35 U S C ___ 119(e)
 ___ 120
 ___ 121
 ___ 365(c)

y respecto de la cual todavía la calidad de pequeña entidad todavía se desea y es apropiado tenerla

___ Se incluye una copia de la declaración

Calculo de la Tasa de Presentación (50% de A, B, o C arriba)

\$380 00

NOTA Cualquier exceso de la tasa completa pagada será reembolsada si se establece el estado de pequeña entidad y si se presenta una solicitud de reembolso dentro de los 2 meses desde la fecha del pago en tiempo de la tasa completa El término de dos meses no es extensible bajo 1 136 37 CFR 1 28(a).

12. **Solicitud para Búsqueda de Tipo Internacional (37 CFR 1.104 (d))**
(EN BLANCO)

13. **Pago de Tasas Canceladas en Este Momento**

X No se adjunta

Angela A. Ponce
ANGELA A. PONCE PATRÓN
Trazador 61
Resol. No. 0177 661/51 Minindustria

53
50

X No es necesario pagar tasa de presentación a este momento
(Esta y la sobretasa ordenada por la Sección 37 CFR 1 16(e) pueden pagarse posteriormente)

___ Se adjunta (EN BLANCO)

14. Método de Pago de Tasas

(EN BLANCO)

15. Autorización para Cargar Tasas Adicionales

(EN BLANCO)

16. Instrucciones para Sobre pago

NOTA " Las cantidades equivalentes a veinticinco dólares o menos no serán reembolsadas a menos que se solicite específicamente dentro de un término razonable ni el pagador será notificado de tales cantidades, cantidades mayores a veinticinco dólares serán reembolsadas mediante cheque o, si se solicita, mediante consignación en una cuenta" 37 CFR Sección 1 26(a)

___ No de Cuenta _____

X Reembolso

Angela A. Pujec
ANGELA A. PUJEC
Traductor e Interpretación Judicial
Resol. No. 0177 del 2011 Ministerio de Justicia

Reg No 27056

(Firma) _____

SA
SI

FIRMA DEL PRACTICANTE

Tel No (978) 526-8000

Donald N Halgren

(escribir nombre del Abogado)

No Cliente

35 Central Street

Dirección Postal

Manchester MA 01944

Angela A. Puri
ANGELA A PURI FIDUCIARY
Trazador e
Resol. No. 0177 del 1997 Minjusticia

52

X

Incorporación por referencia de páginas adicionales

(marcar el siguiente punto si la solicitud en esta transmisión reivindica el beneficio de una(s) solicitud(es) estadounidense(s) anterior(es) (incluyendo una solicitud internacional incluyendo la situación en E.U como una solicitud de continuación, división o C-E-P) y completar y adjuntar las
PAGINAS ADICIONALES PARA LA TRANSMISIÓN DE SOLICITUD NUEVA DONDE SE REIVINDIQUE EL BENEFICIO DE SOLICITUD(ES) ESTADOUNIDENSE(S) ANTERIORES.

X

Mas las Páginas Adicionales por la transmisión de Solicitud Nueva donde se reivindique el Beneficio de Solicitud(es) Estadounidense(s) anterior(es)

Número de Páginas adicionales 5

Declaración donde no se adjuntan páginas adicionales

(EN BLANCO)

Angela A. Puleo
ANGELA A. PULEO
Traductor é
Resol. No 0177 del 19/11/2011

56
53

**PAGINAS ADICIONALES PARA TRANSMISION DE SOLICITUD DONDE SE
REIVINDICA EL BENEFICIO DE SOLICITUD(ES) ESTADOUNIDENSE(S)
ANTERIOR(ES)**

NOTA Ver 37 CFR Sección 1 78

Angela A. Puleo
ANGELA A. PULEO
Traductor & ...
Resol. No. 0177 del ...
Ministerio de Justicia

17. Relacionado Anteriormente

ADVERTENCIA: Si una solicitud reivindica el beneficio de la fecha de presentación de una solicitud presentada con anterioridad bajo la Sección 35 USC 120, 121 o 365(c), el término de 20 años de esa solicitud se fundamentará en la fecha de presentación de la solicitud Estadounidense anterior a la cual se refiere la solicitud bajo la Sección 35 USC 120, 121 o 365 (c) La sección 35 USC 154(a)(2) no tiene en cuenta, para la determinación del término de la patente, aquellas solicitudes donde la prioridad sea reclamada bajo la Sección 35 USC 119, 365(a) o 365(b) Para una solicitud c-e-p, el solicitante deberá revisar si cualquier reivindicación en la patente a concederse está fundamentada en una solicitud anterior y, si no el solicitante deberá considerar la cancelación de la referencia a esa solicitud presentada con anterioridad El término de una patente no se fundamenta en ninguna aproximación de reivindicación por

50
54

reivindicación Ver Aviso de Abril 14 de 1995, 60 Reg Fed 20 195
a 20 205

(completar lo siguiente, si es aplicable)

 X Enmendar la especificación mediante la inclusión antes de la primera línea
de la siguiente frase

A.35 U.S.C. Sección 119(e)
(EN BLANCO)

B. 35 U.S.C. Sección 120, 121 y 365(c)

 X Esta solicitud es una
 ___ continuación
 X continuación en parte
 ___ división

Angela Pulido
ANGELA A. PULIDO, M.A.
Traductor e
Resol. No. 0177 06/15/1995
Ministerio de Justicia

de solicitudes pendientes simultaneamente

 X solicitud número 09 414 250 presentada en 10/7/99 y solicitud No 09-
340 227. presentada en 7/1/99

___ Solicitud Internacional _____ presentada en _____
 ___ la cual designó los E U

(A CONTINUACION EN BLANCO)

**18. Relacionado Anteriormente – Sección 35 U.S.C Sección 119 Reivindicación de
Prioridad por Solicitud Anterior**

(EN BLANCO)

19. Mantenimiento de Codependencia de Solicitud Anterior

(EN BLANCO)

Angela Pulido
ANGELA AL PULIDO
Traductor & i.
Resol. No. 0177 661/91 Minindustria

**20. Declaración Adicional de Titularidad de invención donde se reivindica el
Beneficio de Solicitud(es) Anterior(es)**

(completar asunto aplicable de (a), (b) o (c))

- (a) ☐ Esta solicitud muestra y reivindica solo un asunto del presentado en la solicitud anterior cuyas particularidades se encuentran indicadas arriba y el o los inventores en esta solicitud son
- ☐ los mismos
- ☐ menos que aquellos indicados en la solicitud anterior Se solicita que el siguiente inventor identificado en la solicitud anterior sea eliminado
- _____

- (b) ☒ Esta solicitud muestra y reivindica muestras adicionales mediante enmiendas y se está presentando una nueva declaración o juramento

59
56

Con relación a la solicitud anterior, el (los) inventor(es) en esta solicitud son

X los mismos

_____ los siguientes inventores adicionales se han adicionado

(c) La titularidad de invención de todas las reivindicaciones en esta solicitud son

X las mismas

_____ no las mismas Una explicación, que incluye la titularidad de las diversas reivindicaciones al momento en que la última invención fue reivindicada,

_____ se anexa

_____ será anexada

Angela A. PUI FRIE
ANGELA A. PUI FRIE
Traductor e I.
Resol. No. 0177 del 13/1/1999
Ministerio de Industria

21. Abandono de Solicitud Anterior (si es aplicable)

(EN BLANCO)

22. Petición para Suspensión de ejecución del Tiempo Necesario para Presentar Enmiendas

(EN BLANCO)

23. Pequeña Entidad (38 C F R Sección 1 28 (a))

X El solicitante ha establecido la calidad de pequeña entidad mediante la presentación de una declaración en la solicitud matriz No 09 414 250 el 10/07/99

60
57

_____ Se incluye una copia de la declaración previamente presentada

ADVERTENCIA: Ver Sección 37 CFR 1 28(a)

ADVERTENCIA: "La calidad de pequeña entidad no podrá establecerse cuando una persona o personas que firmen la declaración puedan inequívocamente hacer la auto certificación requerida" M P E P 509 03, 6ta edición, rev 2, Julio 1996 (énfasis agregado)

24. NOTIFICACION EN SOLICITUD MATRIZ DE ESTA PRESENTACIÓN
(EN BLANCO)

Angela Pultrone
ANGELA A. PULTRONE
Traductora C.I.
Resol. No. 0177 del 2011 Industria

Yo Reivindico

- 1 **Una preparación de un compuesto de aplicacion tópica de crema sensibilizadora para aplicar en el epitelio no queratinizado de la mujer, que comprende**
una preparación de L-arginina, y
una preparación de mentol

- 2 **La preparacion de un compuesto de aplicación tópica de crema sensibilizadora para aplicar en el epitelio no queratinizado de la mujer, como se indica en la reivindicación 1, donde dicha preparación de L-arginina tiene una concentracion de 4% o menos**

- 3 **La preparación de un compuesto de aplicación tópica de crema sensibilizadora para aplicar en el epitelio no queratinizado de la mujer, como se indica en la reivindicación 1, donde dicha preparación de mentol tiene una concentración de 5% o menos**

- 4 **La preparacion de un compuesto de aplicacion tópica de crema sensibilizadora para aplicar en el epitelio no queratinizado de la mujer, como se indica en la reivindicación 1, donde dicha preparacion de L-arginina tiene una concentración de 2% y dicha preparación de mentol tiene una concentración de 1%**

- 5 **La preparacion de un compuesto de aplicación tópica de crema sensibilizadora para aplicar en el epitelio no queratinizado de la mujer, como se indica en la reivindicación 1, donde dicha preparacion de L-arginina tiene una concentración de 2% y dicha preparación de mentol tiene una concentración de 1%**

Chalo
ANGELITA PURIFICADO
Traductor e I
Resol. No. 01/7 del 51
Ministerio de Justicia

reivindicación 1, donde dicha preparación compuesta se encuentra contenida en el compartimiento de un aplicador

6 La preparación de un compuesto de aplicación tópica de crema sensibilizadora para aplicar en el epitelio no queratinizado de la mujer, como se indica en la reivindicación 5, donde dicho compartimiento tiene múltiples cámaras

7 La preparación de un compuesto de aplicación tópica de crema sensibilizadora para aplicar en el epitelio no queratinizado de la mujer, como se indica en la reivindicación 5, donde dicho compartimiento está provisto de unos conductos que van desde dicho compartimiento hasta una superficie de contacto exterior con el clitoris sobre dicho aplicador

8 Un método de sensibilización del epitelio no queratinizado de la mujer que comprende los siguientes pasos

aplicación de una preparación de mentol y L-arginina a dicho epitelio

9 Un método de sensibilización del epitelio no queratinizado de la mujer, como se indica en la reivindicación 8, que comprende los siguientes pasos

disposición de dicha preparación de L-arginina en una concentración de menos del 4%, y

disposición de dicha preparación de mentol en una concentración de menos del 5%

10 El metodo de sensibilización del epitelio no queratinizado de la mujer, como se indica en la reivindicación 8, que comprende el siguiente paso

colocación de dichas preparaciones de mentol y L-arginina en un compartimiento del aplicador para su distribución sobre dicho epitelio

11 El método de sensibilización del epitelio no queratinizado de la mujer, como se indica en la reivindicación 8, que comprende el siguiente paso

aplicación de dichas preparaciones en el epitelio de manera consecutiva

Angela A. Pulecio
ANGELA A. PULECIO RAYORBA
Traductor e l. = "l" oficial
Resol No 0177 661/81 Industria

64
61

Resumen de la Invención

La invención comprende una preparación de un compuesto de aplicación tópica de crema sensibilizadora para aplicar en el epitelio no queratinizado de la mujer consistente en una preparación de L-arginina y una preparación de mentol. La preparación de L-arginina tiene una concentración de 4% o menos, y la preparación de mentol tiene una concentración de 5% o menos.

Es traducción fiel de la cual queda copia en el archivo del Traductor para su confrontación, a la cual me remito.

Bogotá D C 29 de Enero de 2001


ANGELA A. PULFERIO MAYORGA
Traductor e Intérprete Judicial
Resol No 0177 del 57 Ministerio de Justicia

PA 345697



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

January 03, 2001

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 09/469,959

FILING DATE: December 21, 1999



By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

P. R. Grant

P. R. GRANT

Certifying Officer

12-27-79

12 67
63

Practitioner's Docket No. Thompson-3

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of
Inventor(s) Thompson, R. J.

WARNING: 37 C.F.R. § 1.41(b)(1) points out:

"(a) A patent is applied for in the name or names of the actual inventor or inventors.

"(1) The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by § 1.63, except as provided for in § 1.63(d)(4) and § 1.63(f). If an oath or declaration as prescribed by § 1.63 is not filed during the pendency of a nonprovisional application, the inventorship is that inventorship set forth in the application papers filed pursuant to § 1.63(f), unless a petition under this paragraph accompanied by the fee set forth in § 1.17(f) is filed supplying or changing the name or names of the inventor or inventors."

For (title): Clitoral Sensitizing Arrangement Using
Compound of Menthol and L-Arginine

CERTIFICATION UNDER 37 C.F.R. 1.10*
(Express Mail label number is mandatory.)
(Express Mail certification is optional.)

I hereby certify that this New Application Transmittal and the documents referred to as attached therein are being deposited with the United States Postal Service on this date 22 Dec 1979 in an envelope as "Express Mail Post Office to Addressee," mailing Label Number EE 8313512530, addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

S. N. Helgren
(Type or print name of person mailing paper)

[Signature]
Signature of person mailing paper

WARNING: Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing, 37 C.F.R. 1.10(f).
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1988, 60 Fed. Reg. 58,438, at 58,442.

(Application Transmittal [4-1]—page 1 of 11)

JCSB3 U S PTO
12/21/99

JCSB3 U S PTO
09/469959
12/18/99

469959-122199

68
64

WARNING: When the last day of pendency of a provisional application falls on a Saturday, Sunday, or Federal holiday within the District of Columbia, any nonprovisional application claiming benefit of the provisional application must be filed prior to the Saturday, Sunday, or Federal holiday within the District of Columbia. See 37 C.F.R. § 1.784(c)(2).

- ☐ The new application being transmitted claims the benefit of prior U.S. application(s). Enclosed are ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

3. Papers Enclosed

- A. Required for filing date under 37 C.F.R. § 1.53(b) (Regular) or 37 C.F.R. § 1.153 (Design) Application**

15 Pages of specification

3 Pages of claims

1 Sheets of drawing

WARNING: *DO NOT* submit original drawings. A high quality copy of the drawings should be supplied when filing a patent application. The drawings that are submitted to the Office must be on strong, white, smooth, and non-reflective paper and meet the standards according to § 1.84. If corrections to the drawings are necessary, they should be made to the original drawing and a high-quality copy of the corrected original drawing then submitted to the Office. Only one copy is required or desired. For comments on proposed then-new 37 CFR 1.84, see Notice of March 5, 1998 (1980 O.G. 57-52).

NOTE: "Identifying indicia, if provided, should include the application number or the title of the invention, inventor's name, docket number (if any), and the name and telephone number of a person to call if the Office is unable to match the drawings to the proper application. This information should be placed on the back of each sheet of drawing a minimum distance of 1.5 cm. (5/8 inch) down from the top of the page." 37 C.F.R. 1.846-5.

(complete the following, if applicable)

- ☐ The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)." 37 C.F.R. 1.84(b).

- ☐ formal
☒ informal

B. Other Papers Enclosed

____ Pages of declaration and power of attorney

1 Pages of abstract

Other

4. Additional papers enclosed

- ☐ Amendment to claims
 - ☐ Cancel in this applications claims _____ before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
 - ☐ Add the claims shown on the attached amendment. (Claims added have been numbered consecutively following the highest numbered original claims.)
- ☐ Preliminary Amendment
- ☐ Information Disclosure Statement (37 C.F.R. 1.95)
- ☐ Form PTO-1449 (PTO/SB/08A and 08B)
- ☐ Citations

0946464646 - 1221

1 Type of Application

This new application is for a(n)

(check one applicable item below)

- ☒ Original (nonprovisional)
☐ Design
☐ Plant

WARNING: Do not use this transmittal for a completion in the U.S. of an International Application under 35 U.S.C. 371(c)(4), unless the International Application is being filed as a divisional, continuation or continuation-in-part application.

WARNING: Do not use this transmittal for the filing of a provisional application.

NOTE: If one of the following 3 items apply, then complete and attach **ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF A PRIOR U.S. APPLICATION CLAIMED** and a **NOTIFICATION IN PARENT APPLICATION OF THE FILING OF THIS CONTINUATION APPLICATION**.

- ☐ Divisional
☐ Continuation.
☒ Continuation-in-part (C-I-P).

2. Benefit of Prior U.S. Application(s) (35 U.S.C. 119(e), 120, or 121)

NOTE: A nonprovisional application may claim an invention disclosed in one or more prior filed expending nonprovisional applications or expending International applications designating the United States of America. In order for a nonprovisional application to claim the benefit of a prior filed expending nonprovisional application or expending International application designating the United States of America, each prior application must name as an inventor at least one inventor named in the later filed nonprovisional application and disclose the named inventor's invention claimed in at least one claim of the later filed nonprovisional application in the manner provided by the first paragraph of 35 U.S.C. 112. Each prior application must also be:

(i) An International application entitled to a filing date in accordance with PCT Article 11 and designating the United States of America, or

(ii) Complete as set forth in § 1.51(b); or

(iii) Entitled to a filing date as set forth in § 1.53(b) or § 1.53(c) and include the basic filing fee set forth in § 1.18; or

(iv) Entitled to a filing date as set forth in § 1.53(b) and have paid therein the processing and retention fee set forth in § 1.21(f) within the time period set forth in § 1.53(d).

37 C.F.R. § 1.78(b)(1).

NOTE: If the new application being transmitted is a divisional, continuation or a continuation-in-part of a parent case, or where the parent case is an International Application which designated the U.S., or benefit of a prior provisional application is claimed, then check the following item and complete and attach **ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED**.

WARNING: If an application claims the benefit of the filing date of an earlier filed application under 35 U.S.C. 120, 121 or 365(a), the 20-year term of that application will be based upon the filing date of the earliest U.S. application that the application makes reference to under 35 U.S.C. 120, 121 or 365(a). (35 U.S.C. 154(b)(2) does not take into account, for the determination of the patent term, any application on which priority is claimed under 35 U.S.C. 119, 365(a) or 365(b).) For a c-i-p application, applicant should review whether any claim in the patent that will issue is supported by an earlier application and, if not, the applicant should consider canceling the reference to the earlier filed application. The term of a patent is not based on a claim-by-claim approach. See Notice of April 14, 1985, 60 Fed. Reg. 20,195, at 20,205.

(Application Transmittal [4-1]—page 2 of 11)

0946 959-122199

68
65

70
66

- ☐ Declaration of Biological Deposit
- ☐ Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence
- ☐ Authorization of Attorney(s) to Accept and Follow Instructions from Representative
- ☐ Special Comments
- ☐ Other

5. Declaration or oath (including power of attorney)

NOTE: A newly executed declaration is not required in a continuation or divisional application provided that the prior nonprovisional application contained a declaration as required, the application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application (showing the signature or an indication thereon that it was signed) is submitted. The copy must be accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application was filed under § 1.47, then a copy of that declaration must be filed accompanied by a copy of the decision granting § 1.47 status or, if a noninventing person under § 1.47 has subsequently joined in a prior application, then a copy of the subsequently executed declaration must be filed. See 37 C.F.R. §§ 1.634(f)(1)-(3).

NOTE: A declaration filed to complete an application must be executed, identify the specification to which it is directed, identify each inventor by full name including family name and at least one given name, without abbreviation together with any other given name or initial, and the residence, post office address and country or citizenship of each inventor, and state whether the inventor is a sole or joint inventor 37 C.F.R. § 1.634(f)(1)-(4).

- ☐ Enclosed

Executed by

(check all applicable boxes)

- ☐ Inventor(s).
- ☐ legal representative of inventor(s)
37 CFR 1.42 or 1.43
- ☐ Joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached.
- ☐ This is the petition required by 37 CFR 1.47 and the statement required by 37 CFR 1.47 is also attached. See Item 13 below for fee.

- ☒ Not Enclosed.

NOTE: Where the filing is a completion in the U.S. of an International Application or where the completion of the U.S. application contains subject matter in addition to the International Application, the application may be treated as a continuation or continuation-in-part, as the case may be, utilizing **ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION CLAIMED.**

- ☐ Application is made by a person authorized under 37 C.F.R. 1.41(c) on behalf of all the above named inventor(s)

(The declaration or oath, along with the surcharge required by 37 CFR 1.16(e) can be filed subsequently).

- ☐ Showing that the filing is authorized.
(not required unless called into question. 37 CFR 1.41(d))

(Application Transmittal [4-1]—page 4 of 11)

4 9959.122199

71
67

6. Inventorship Statement

WARNING: If the named inventors are each not the inventors of all the claims an explanation, including the ownership of the various claims at the time the last claimed invention was made, should be submitted.

The inventorship for all the claims in this application are:

☒ The same.

or

☐ Not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made,

☐ is submitted.

☐ will be submitted.

7. Language

NOTE: An application including a signed oath or declaration may be filed in a language other than English. An English translation of the non-English language application and the processing fee of \$130.00 required by 37 CFR 1.17(b) is required to be filed with the application, or within such time as may be set by the Office. 37 CFR 1.52(d).

☒ English

☐ Non-English

☐ The attached translation includes a statement that the translation is accurate. 37 C.F.R. 1.52(d).

8. Assignment

☒ An assignment of the invention to 401'S LLC

☐ is attached. A separate ☐ "COVER SHEET FOR ASSIGNMENT (DOCUMENT) ACCOMPANYING NEW PATENT APPLICATION" or ☐ FORM PTO 1595 is also attached.

☒ will follow.

NOTE: If an assignment is submitted with a new application, send two separate letters—one for the application and one for the assignment." Notice of May 4, 1990 (1114 O.G. 77-78).

WARNING: A newly executed "CERTIFICATE UNDER 37 CFR 3.73(b)" must be filed when a continuation-in-part application is filed by an assignee. Notice of April 30, 1993, 1190 O.G. 62-64.

(Application Transmitted [4-1]—page 6 of 11)

094 9859.12219
61221.6586 460

7C
68

9. Certified Copy

Certified copy(ies) of application(s)

Country	Appn. No.	Filed
---------	-----------	-------

Country	Appn. No.	Filed
---------	-----------	-------

Country	Appn. No.	Filed
---------	-----------	-------

from which priority is claimed

☐ is (are) attached

☐ will follow

NOTE: The foreign application forming the basis for the claim for priority must be referred to in the oath or declaration. 37 CFR 1.58(a) and 1.63.

NOTE: This item is for any foreign priority for which the application being filed directly relates. If any parent U.S. application or International Application from which this application claims benefit under 35 U.S.C. 120 is itself entitled to priority from a prior foreign application, then complete item 18 on the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

10. Fee Calculation (37 C.F.R. 1.16)

A. ☒ Regular application

CLAIMS AS FILED			
Number filed	Number Extra	Rate	Basic Fee 37 C.F.R. 1.16(a) \$790.00
Total Claims (37 CFR 1.16(c)) 11 - 20 =	—	x	\$ 22.00
Independent Claims (37 CFR 1.16(b)) 7 - 3 =	—	x	\$ 82.00
Multiple dependent claim(s), if any (37 CFR 1.16(d))		+	\$270.00

☐ Amendment cancelling extra claims is enclosed.

☐ Amendment deleting multiple-dependencies is enclosed.

☐ Fee for extra claims is not being paid at this time.

NOTE: If the fees for extra claims are not paid on filing they must be paid or the claims cancelled by amendment, prior to the expiration of the time period set for response by the Patent and Trademark Office in any notice of fee delinquency. 37 CFR 1.16(f).

Filing Fee Calculation

\$ 762.00

B. ☐ Design application
(\$330.00—37 CFR 1.16(n))

Filing Fee Calculation

\$

C. ☐ Plant application
(\$540.00—37 CFR 1.16(g))

Filing fee calculation

\$

(Application Transmittal [4-1]—page 6 of 11)

661221-566 46
94 995 122199

73
69

11. Small Entity Statement(s)

☒ Statement(s) that this is a filing by a small entity under 37 CFR 1.9 and 1.27 is (are) attached: will be filed

WARNING: Status as a small entity must be specifically established in each application or patent in which the status is available and desired. Status as a small entity in one application or patent does not affect any other application or patent, including applications or patents which are directly or indirectly dependent upon the application or patent in which the status has been established. The refile of an application under § 1.53 as a continuation, division, or continuation-in-part (including a continued prosecution application under § 1.53(a)), or the filing of a reissue application requires a new determination as to continued entitlement to small entity status for the continuing or reissue application. A nonprovisional application claiming benefit under 35 U.S.C. 119(b), 120, 121, or 365(c) of a prior application, or a reissue application may rely on a statement filed in the prior application or in the patent if the nonprovisional application or the reissue application includes a reference to the statement in the prior application or in the patent or includes a copy of the statement in the prior application or in the patent and status as a small entity is still proper and desired. The payment of the small entity basic statutory filing fee will be treated as such a reference for purposes of this section." 37 C.F.R. § 1.28(b)(2).

(complete the following, if applicable)

- ☐ Status as a small entity was claimed in prior application

_____ / _____, filed on _____, from which benefit is being claimed for this application under:

- 35 U.S.C. ☐ 119(e),
☐ 120,
☐ 121,
☐ 365(c),

and which status as a small entity is still proper and desired.

- ☐ A copy of the statement in the prior application is included.

Filing Fee Calculation (50% of A, B or C above)

\$ 380.00

NOTE: Any excess of the full fee paid will be refunded if small entity status is established and a refund request are filed within 2 months of the date of timely payment of a full fee. The two-month period is not extendable under § 1.136, 37 CFR 1.28(b).

12. Request for International-Type Search (37 C.F.R. 1.104(d))

(complete, if applicable)

- ☐ Please prepare an international-type search report for this application at the time when national examination on the merits takes place.

(Application Transmitted [4-1]—page 7 of 11)

0 4 9959-122199

74
70

13. Fee Payment Being Made at This Time

☒ Not Enclosed

☒ No filing fee is to be paid at this time.
(This and the surcharge required by 37 C.F.R. 1.16(e) can be paid subsequently.)

☐ Enclosed

☐ Filing fee \$ _____

☐ Recording assignment
(\$40.00; 37 C.F.R. 1.21(f))
(See attached "COVER SHEET FOR
ASSIGNMENT ACCOMPANYING NEW
APPLICATION") \$ _____

☐ Petition fee for filing by other than all the
inventors or person on behalf of the inventor
where inventor refused to sign or cannot be
reached
(\$130.00; 37 C.F.R. 1.47 and 1.17(g)) \$ _____

☐ For processing an application with a
specification in
a non-English language
(\$130.00; 37 C.F.R. 1.52(d) and 1.17(h)) \$ _____

☐ Processing and retention fee
(\$130.00; 37 C.F.R. 1.53(d) and 1.21(i)) \$ _____

☐ Fee for international-type search report
(\$40.00; 37 C.F.R. 1.21(e)) \$ _____

NOTE: 37 CFR 1.21(i) establishes a fee for processing and retaining any application that is abandoned for failing to complete the application pursuant to 37 CFR 1.53(i) and this, as well as the changes to 37 CFR 1.53 and 1.78(i)(1), indicate that in order to obtain the benefit of a prior U.S. application, either the basic filing fee must be paid, or the processing and retention fee of § 1.21(i) must be paid, within 1 year from notification under § 63(i).

Total fees enclosed \$ _____

14. Method of Payment of Fees

☐ Check in the amount of \$ _____

☐ Charge Account No _____ in the amount of
\$ _____

A duplicate of this transmittal is attached.

NOTE: Fees should be itemized in such a manner that it is clear for which purpose the fees are paid. 37 CFR 1.22(b).

(Application Transmittal [4-1]-page 8 of 11)

4 9959-122199 661221-6566

15. Authorization to Charge Additional Fees

WARNING: If no fee are to be paid on filing, the following items should not be completed.

WARNING: Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges, if extra claim charges are authorized.

- ☐ The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. _____

☐ 37 C.F.R. 1.16(a), (f) or (g) (filing fees)

☐ 37 C.F.R. 1.16(b), (c) and (d) (presentation of extra claims)

NOTE: Because additional fees for excess or multiple dependent claims not paid on filing or on later presentation must only be paid or these claims cancelled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 CFR 1.16(g)), it might be best not to authorize the PTO to charge additional claim fees, except possibly when dealing with amendments after final action.

☐ 37 C.F.R. 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)

☐ 37 C.F.R. §§ 1.17(a)(1)-(5) (extension fees pursuant to § 1.136(a)).

☐ 37 C.F.R. 1.17 (application processing fees)

NOTE: "A written request may be submitted in an application that is an authorization to treat any concurrent or future reply, requiring a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. An authorization to charge all required fees, fees under § 1.17, or all required extension of time fees will be treated as a constructive petition for an extension of time in any concurrent or future reply requiring a petition for an extension of time under this paragraph for its timely submission. Submission of the fee set forth in § 1.17(a) will also be treated as a constructive petition for an extension of time in any concurrent reply requiring a petition for an extension of time under this paragraph for its timely submission." 37 C.F.R. § 1.136(a)(3).

☐ 37 C.F.R. 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. 1.311(b)).

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance. 37 CFR 1.311(b).

NOTE: 37 CFR 1.289 requires "Notification of any change in status resulting in loss of entitlement to small entity status must be filed in the application . . . prior to paying, or at the time of paying, . . . the issue fee. . . From the wording of 37 CFR 1.289(b), (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.

(Application Transmittal [4-1]—page 9 of 11)

94 859.1221 6

76
72

16. Instructions as to Overpayment


NOTE: " Amounts of twenty-five dollars or less will not be returned unless specifically requested within a reasonable time, nor will the payer be notified of such amounts; amounts over twenty-five dollars may be returned by check or, if requested, by credit to a deposit account." 37 C.F.R. § 1.204.

- ☐ Credit Account No. _____
☒ Refund

Reg. No. 27056

Tel. No. A18 526-8000

Customer No.



SIGNATURE OF PRACTITIONER

Donald N. Halgren

(Type or print name of attorney)

35 Central Street

P.O. Address

Manchester MA 01944

(Application Transmittal (4-1)—page 10 of 11)

45 55.122199

77
73

☒ Incorporation by reference of added pages

(check the following item if the application in this transmittal claims the benefit of prior U.S. application(s) (including an international application entering the U.S. stage as a continuation, divisional or C-I-P application) and complete and attach the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED)

☒ Plus Added Pages for New Application Transmittal Where Benefit of Prior U.S. Application(s) Claimed

Number of pages added 5

☐ Plus Added Pages for Papers Referred to in Item 4 Above

Number of pages added _____

☐ Plus added pages deleting names of inventor(s) named in prior application(s) who is/are no longer inventor(s) of the subject matter claimed in this application.

Number of pages added _____

☐ Plus "Assignment Cover Letter Accompanying New Application"

Number of pages added _____

☐ Statement Where No Further Pages Added

(if no further pages form a part of this Transmittal, then end this Transmittal with this page and check the following item)

☐ This transmittal ends with this page.

661221-65 6 116

70
74

Practitioner's Docket No. Thompson-3

PATENT

ADDED PAGES FOR APPLICATION TRANSMITTAL WHERE BENEFIT OF
PRIOR U.S. APPLICATION(S) CLAIMED

NOTE: See 37 C.F.R. § 1.78.

17. Relate Back

WARNING: If an application claims the benefit of the filing date of an earlier filed application under 35 U.S.C. §§ 120, 121 or 365(c), the 20-year term of that application will be based upon the filing date of the earliest U.S. application that the application makes reference to under 35 U.S.C. §§ 120, 121 or 365(c). (35 U.S.C. § 154(a)(2) does not take into account, for the determination of the patent term, any application on which priority is claimed under 35 U.S.C. §§ 119, 365(a) or 365(c).) For a o-i-p application, applicant should review whether any claim in the patent that will issue is supported by an earlier application and, if not, the applicant should consider canceling the reference to the earlier filed application. The term of a patent is not based on a claim-by-claim approach. See Notice of April 14, 1995, 60 Fed. Reg. 20,186, at 20,206.

(complete the following, if applicable)

☒ Amend the specification by inserting, before the first line, the following sentence:

A. 35 U.S.C. § 119(e)

NOTE: "Any nonprovisional application claiming the benefit of one or more prior filed pending provisional applications must contain or be amended to contain in the first sentence of the specification following the title a reference to each such prior provisional application, identifying it as a provisional application, and including the provisional application number (consisting of series code and serial number)." 37 C.F.R. § 1.78(a)(4).

☐ "This application claims the benefit of U.S. Provisional Application(s) No(s)...

APPLICATION NO(S):	FILING DATE
_____ / _____	_____ "
_____ / _____	_____ "
_____ / _____	_____ "

094 995 -122199

74
75

B. 35 U.S.C. §§ 120, 121 and 365(c)

NOTE: "Except for a continued prosecution application filed under § 1.53(d), any nonprovisional application claiming the benefit of one or more prior filed copending nonprovisional applications or international applications designating the United States of America must contain or be amended to contain in the first sentence of the specification following the title a reference to each such prior application, identifying it by application number (consisting of the series code and serial number) or international application number and international filing date and indicating the relationship of the applications. Cross-references to other related applications may be made when appropriate." (See § 1.14(h), 37 C.F.R. § 1.78(d)(2).)

- ☒ This application is a
- ☐ continuation
 - ☒ continuation-in-part
 - ☐ divisional

of copending application(s)

- ☒ application number 09/414,250 filed on 10/07/09.
- ☐ International Application _____ filed on _____

_____ and which designated the U.S."

NOTE: The proper reference to a prior filed PCT application that entered the U.S. national phase is the U.S. serial number and the filing date of the PCT application that designated the U.S.

NOTE: (1) Where the application being transmitted adds subject matter to the International Application, then the filing can be as a continuation-in-part or (2) if it is desired to do so for other reasons than the filing can be as a continuation.

NOTE: The deadline for entering the national phase in the U.S. for an international application was clarified in the Notice of April 28, 1987 (1079 O.G. 32 to 48) as follows.

"The Patent and Trademark Office considers the international application to be pending until the 22nd month from the priority date if the United States has been designated and no Demand for International Preliminary Examination has been filed prior to the expiration of the 18th month from the priority date and until the 32nd month from the priority date if a Demand for International Preliminary Examination which elected the United States of America has been filed prior to the expiration of the 18th month from the priority date, provided that a copy of the international application has been communicated to the Patent and Trademark Office within the 20 or 30 month period respectively. If a copy of the international application has not been communicated to the Patent and Trademark Office within the 20 or 30 month period respectively, the international application becomes abandoned as to the United States 20 or 30 months from the priority date respectively. These periods have been placed in the rules as paragraph (f) of § 1.484 and paragraph (f) of § 1.485. A continuing application under 35 U.S.C. 365(c) and 120 may be filed anytime during the pendency of the international application."

- ☐ "The nonprovisional application designated above, namely application _____ / _____, filed _____, claims the benefit of U.S. Provisional Application(s) No(s)_____.

APPLICATION NO(S):

FILING DATE

_____/_____
_____/_____
_____/_____

- ☐ Where more than one reference is made above, please combine all references into one sentence.

0946 959 122199

80
76

18. Relate Back—35 U.S.C. § 119 Priority Claim for Prior Application

The prior U.S. application(s), including any prior International Application designating the U.S., identified above in item 17B, in turn itself claim(s) foreign priority(ies) as follows:

Country	Appl. no.	Filed on
---------	-----------	----------

The certified copy(ies) has (have)

- ☐ been filed on _____ in prior application 0 / _____, which was filed on _____
- ☐ is (are) attached.

WARNING: The certified copy of the priority application that may have been communicated to the PTO by the International Bureau may not be relied on without any need to file a certified copy of the priority application in the continuing application. This is so because the certified copy of the priority application communicated by the International Bureau is placed in a folder and is not assigned a U.S. serial number unless the national stage is entered. Such folders are disposed of if the national stage is not entered. Therefore, such certified copies may not be available if needed later in the prosecution of a continuing application. An alternative would be to physically remove the priority documents from the folders and transfer them to the continuing application. The resources required to request transfer, retrieve the folders, make suitable record notations, transfer the certified copies, enter and make a record of such copies in the Continuing Application are substantial. Accordingly, the priority documents in folders of International applications that have not entered the national stage may not be relied on. Notice of April 28, 1967 (1079 O.G. 32 to 46).

19. Maintenance of Dependency of Prior Application

NOTE: The PTO finds it useful if a copy of the petition filed in the prior application extending the term for response is filed with the papers constituting the filing of the continuation application. Notice of November 6, 1968 (1080 O.G. 27).

- A. ☐ Extension of time in prior application

(This item must be completed and the papers filed in the prior application, if the period set in the prior application has run.)

- ☐ A petition, fee and response extends the term in the pending prior application until _____
- ☐ A copy of the petition filed in prior application is attached

- B. ☐ Conditional Petition for Extension of Time in Prior Application

(complete this item, if previous item not applicable)

- ☐ A conditional petition for extension of time is being filed in the pending prior application
- ☐ A copy of the conditional petition filed in the prior application is attached.

09469999.122199

94
77

20. Further Inventership Statement Where Benefit of Prior Application(s) Claimed

(complete applicable item (a), (b) and/or (c) below)

- (a) ☐ This application discloses and claims only subject matter disclosed in the prior application whose particulars are set out above and the inventor(s) in this application are
- ☐ the same.
 - ☐ less than those named in the prior application. It is requested that the following inventor(s) identified for the prior application be deleted:

(type name(s) of inventor(s) to be deleted)

- (b) ☒ This application discloses and claims additional disclosure by amendment and a new declaration or oath is being filed. With respect to the prior application, the inventor(s) in this application are
- ☒ the same.
 - ☐ the following additional inventor(s) have been added:

(type name(s) of inventor(s) to be added)

- (c) The inventership for all the claims in this application are
- ☒ the same.
 - ☐ not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made
 - ☐ is submitted.
 - ☐ will be submitted

0 4 959-122199

78

21. Abandonment of Prior Application (if applicable)

- ☐ Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application copending with said prior application.

NOTE: According to the Notice of May 13, 1983 (103, TMOG 6-7), the filing of a continuation or continuation-in-part application is a proper response with respect to a petition for extension of time or a petition to revive and should include the express abandonment of the prior application conditioned upon the granting of the petition and the granting of a filing date to the continuing application.

22. Petition for Suspension of Prosecution for the Time Necessary to File an Amendment

WARNING: "The claims of a new application may be finally rejected in the first Office action in those situations where (1) the new application is a continuing application of, or a substitute for, an earlier application, and (2) all the claims of the new application (a) are drawn to the same invention claimed in the earlier application, and (b) would have been properly finally rejected on the grounds of art of record in the next Office action if they had been entered in the earlier application." M.P.E.P., § 706.07(b), 6th ed., rev. 2.

NOTE: Where it is possible that the claims on file will give rise to a first action final for this continuation application and for some reason an amendment cannot be filed promptly (e.g., experimental data is being gathered) it may be desirable to file a petition for suspension of prosecution for the time necessary.

(check the next item, if applicable)

- ☐ There is provided herewith a Petition To Suspend Prosecution for the Time Necessary to File An Amendment (New Application Filed Concurrently)

23. Small Entity (37 C.F.R. § 1.28(a))

- ☒ Applicant has established small entity status by the filing of a statement in parent application 1,414,752 on 10/07/04
- ☐ A copy of the statement previously filed is included.

WARNING: See 37 C.F.R. § 1.28(a).

WARNING: "Small entity status must not be established when the person or persons signing the statement can unequivocally make the required self-certification." M.P.E.P., § 508.03, 6th ed., rev. 2, July 1996 (emphasis added).

24. NOTIFICATION IN PARENT APPLICATION OF THIS FILING

- ☐ A notification of the filing of this (check one of the following)
- ☐ continuation
 - ☐ continuation-in-part
 - ☐ divisional

is being filed in the parent application, from which this application claims priority under 35 U.S.C. § 120.

(Added Pages for Application Transmitted Where Benefit of Prior U.S. Application(s) Claimed [4-11]—page 6 of 8)

09469959-122199

63
79

Thompson-3

Clitoral Sensitizing Arrangement Using Compound of Menthol and L-Arginine

Background of the Invention

Field of the Invention

This invention relates to arrangements for the stimulation of females and more particularly to topical compounds and arrangements for applying such compounds to the clitoris of females to improve their sexual sensation, and is a continuation-in-part application of U.S. Patent Application serial no.: 09/414,250, filed 10/07/99, which is a continuation-in-part application of U.S. Patent Application serial no.: 09/340,227, filed 07/01/99, both of which are incorporated herein by reference in their entirety.

Prior Art

In the human female, decreased clitoral sensitivity and responsiveness are related to normal aging, relative or absolute estrogen and testosterone deficiency (either as a consequence of medicines or aging), and by a host of vascular conditions such as diabetes and hypertension. Multiple laboratory

661221-6566946

89
80

and clinical research endeavors have been directed toward male erectile dysfunction (ED), yielding not only an understanding of the erection physiology, but also medications to treat ED, such as Viagra™. Very little research has been initiated to understand or address female physiological sexual unresponsiveness. However, since the penis and the clitoris are analogous anatomical structures, the basic cellular and physiological knowledge about male penile erections translates to functions of the clitoris.

Female clitoral dysfunction is extremely difficult to document and quantify. A number of modalities, such as Doppler blood flow, precise temperature measurements, and actual imaging measurements, have been employed to attempt to define clitoral responsiveness - all with results unsatisfactory for meaningful research. Estimates that 15 million U.S. men suffer from erectile dysfunction have been reported in the literature. A recent article in the February 10, 1999 issue of the *Journal of the American Medical Association* suggests that female erectile dysfunction occurs probably twice the rate of male ED, therefore affecting 30 million U.S. women.

09469959-12219

85
81

In the female anatomy, the clitoral artery is located in the middle of the clitoris, extending lengthwise from the base to the tip of the clitoris, and supplies blood to the clitoris. Two clitoral veins are located on either side of the clitoral artery, and normally drain the clitoris of the blood pumped into it from the artery. As female sexual arousal initiates, either by direct stimulation of the clitoris or by the application of one of the recently developed female arousal creams, the vessels dilate and the valves of the clitoral veins located at the base of the clitoris close. The venous blood fills two honeycomb-like chambers, the corpus cavernosa. The corpus cavernosa are normally empty of blood, but, like the clitoral artery and veins, they are positioned lengthwise from the base to the tip of the clitoris. Therefore, as the valves in the veins at the base of the clitoris close, the blood pumped into the clitoris artery distends the corpus cavernosa. This causes the clitoris to enlarge two-to-three fold, and to become erect, rigid, and highly sensitive, just as the penis in the male. In fact, the penis and the clitoris are the exact same structures. Female clitoral enlargement and rigidity and male penile erection are both accomplished by the same action: vasodilation of the vascular structures maximally distending the corpus cavernosa.

094 9959.122199

Topical application of medications to different types of Integument (skin) to effect changes in sensation are based upon that type of integument. There are two types of integument (skin): keratinized stratified squamous epithelium, and non-keratinized stratified squamous epithelium, more commonly referred to as mucous membrane. The entire external surface of the body is covered with keratinized stratified squamous epithelium except the lips, mouth, anus, and the vagina/vulva in females. If a lotion is applied to the keratinized squamous epithelium, it is absorbed only by the top layers of the skin. Multiple transdermal medications are delivered through the keratinized skin, but the delivery system is very sophisticated. Absorption of medications is much easier if they are delivered to mucous membranes, or non-keratinized stratified squamous epithelium, especially the vulva and vaginal mucosa. Many vaginal creams and suppositories that dissolve to become creams with the moisture and heat of the vagina have been sold for over fifty years. All of the vaginal creams and suppositories are absorbed into full thickness of the non-keratinized stratified squamous epithelium that defines the vaginal mucosa. Some of the vaginal creams are systemically absorbed by the blood vessels in the basement membrane of the vaginal mucosa, while other medications are not systemically absorbed. Systemic absorption refers to the distribution of the medication throughout all tissues

of the body via the blood stream. The vaginal/vulvar mucosa is a multiple layer of non-keratinized stratified squamous epithelial cells twenty-to-thirty cells in thickness from the basement membrane to the outermost cells of the mucosa.

The integument of the undercarriage of the clitoris is non-keratinized stratified squamous epithelium (mucous membrane), and topical medications are readily absorbed. The clitoral hood that covers the dorsal aspect of the clitoris is partially keratinized, and allows partial absorption of topical medications. The integument of the penis is keratinized stratified squamous epithelium. Absorption of the same medication topically applied to the penis and the clitoris concurrently will be much more readily absorbed by the clitoris because of the mucous membrane of the clitoris.

Topical menthol is a clitoral sensitizing agent and may be applied clitoral tissue and may have a number of effects. The specific effects that menthol causes are dependent upon three variables: the concentration of the menthol in the preparation, the vehicle and its evaporation properties, and most importantly, the type of tissue to which the menthol is applied. If the menthol is in a non-evaporating vehicle and applied to keratinized stratified

0 46995 -12219 612219

88
84

squamous epithelium (hairy skin), a low concentration is under 1%, a mid-range concentration, 1%-5%, and a high concentration, between 5% and 10%. If menthol in a non-evaporating vehicle is applied to non-keratinized stratified squamous epithelium (mucous membrane), a low concentration is less than 0.5%, a mid-range concentration between 0.5% and 2%, and a high concentration between 2% and 5%. Therefore, a 1% concentration of menthol in a non-evaporating vehicle applied to keratinized and non-keratinized epithelium would produce very different effects: the keratinized epithelium would respond with a minimal effect, while the non-keratinized epithelium would respond with a marked effect. This is because of the rapid absorption through the non-keratinized epithelium (mucous membrane) and the relatively poor absorption through the barrier-like keratinized epithelium (hairy skin).

Menthol is highly lipid-soluble and readily absorbed by a mucous membrane. A mid-range concentration of 0.5% to 2% of menthol topically applied to mucous membrane causes almost immediate smooth muscle relaxation, hyperemia, and vasodilation of blood vessels by a direct response. Menthol also causes the immediate stimulation of both thermoreceptors and nociceptors. The thermoreceptors, when stimulated,

BP
35

create a sensation of warmth and burning for this menthol concentration in mucous membrane (like the clitoris). The nociceptors initiate an axon reflex to release vasodilator peptides. The vasodilator peptides cause an immediate vasodilation of blood vessels with resultant blood engorgement and transudate production. The sera component of the blood that leaks out of the blood vessels to provide increased vaginal/vulvar lubrication is due to the nociceptor initiated vasodilation. The onset of all of these mechanisms occurs within thirty seconds of application of the menthol preparation, and these responses persist for fifteen-to-twenty minutes. Therefore, the topical application of a 1% menthol preparation, in a non-evaporating vehicle directly to the mucous membrane of the clitoris, causes the following physiological responses: a. warmth, tingling, and even mild burning; b. hyperemia; c. direct smooth muscle relaxation; d. indirect blood engorgement via nociceptor-mediated vasodilation by peptide release; and e. increased vulvar/vaginal lubrication.

Topical L-arginine is a clitoral sensitizing agent, produced from intracellular nitric acid (NO) , which is a potent vasodilator of smooth muscles, and has been identified and confirmed by a number of research studies to be pivotally involved in penile/clitoral erections. Nitric oxide is synthesized

1 98
86

from the substrate L-arginine in a cellular reaction catalyzed by nitric oxide synthase (NOS). Two different types of NOS have been identified: eNOS and nNOS. The eNOS is contained with the smooth muscle endothelial cells that line the vasculature of the penis/clitoris. As the available L-arginine is converted into NO by eNOS, the blood vessels and corpus cavernosa of the penis/clitoris dilate and fill with blood. This engorgement of the penis/clitoris is the mechanism for the erection and rigidity of the aroused penis/clitoris. The nNOS is contained within the nerve cells of the penis/clitoris and converts L-arginine into NO to sensitize the penis/clitoris and cause the release of vasodilation peptide. Burnett, et al. reported in "Immunohistochemical Description of Nitric Oxide Synthase Isoforms in Human Clitoris", *Journal of Urology*, July 1997, 75-79, that the vascular and neuronal alteration of the penis/clitoris that create an erection are the direct effect of the ability of the cells to convert the available L-arginine into nitric oxide through nitric oxide synthase.

Several urologic and gynecologic reports have identified a correlation between a decreased availability or activity of the NO synthase system and normal aging, testosterone deficiency, and estrogen deficiency. The studies confirm that an increase in the supply of the substrate L-arginine allows the

27

attenuated but still functional NOS system to affect the nitric oxide mediated erection of the penis/clitoris. Therefore, the topical application of L-arginine via the NOS system causes vasodilation of the penile/clitoral venous structures and concomitant sensitivity.

The safety of 1% of 2% menthol topically applied to the clitoris is a consideration. Two different strengths of menthol may be commercialized, such as 1% and 2% concentrations in a non-evaporating water base. The anticipated normal volume of such cream to be applied to the clitoris is 300 mg. Therefore, the maximum amount of menthol delivered is 6 mg. *The Extra Pharmacopoeia*, Martindale, 1989, reports menthol toxicity for humans at 28 mg./kg. In a 50 kg individual, the toxic dose could be 1400 mg., but this is estimated to be extremely low by Eccles in his "Review: Menthol and Other Cooling Compounds" in the 1994 *Journal of Pharmacological Pharmacopoeia*, volume 46, pages 618-630. A 6 mg. dose of menthol is well below the 1400 mg. dose calculated and gives a 100 plus fold margin of safety.

The safety of L-arginine topically applied to the clitoris is also a consideration. Two different strengths of L-arginine USP, 2% and 4%, may

92
88

be marketed so as to sensitize the clitoris. The anticipated normal volume of such cream to be applied to the clitoris is 300 mg. Therefore, a maximum of 12 mg. Of L-arginine USP is available. If all 12 mg. are systemically absorbed, this is a small fraction of what has been reported in the gynecologic literature as safe. Fracchinette, et al., reported the intravenous infusion of 30 grams (30,000 milligrams) of L-arginine into 29 pregnant patients without adverse effects in the 1999 *Journal of the Society of Gynecologic Investigation*, volume 6,202-207.

Brief Summary of the Invention

Unique properties of a combination menthol/L-arginine topical clitoral sensitizing preparation provides the basis of the present invention. Sequential application first by menthol applied topically to the mucous membrane of the clitoris has an almost immediate response by affecting vasodilation and blood engorgement warmth (via the thermoreceptors). The duration of menthol's action on mucous membranes may be for fifteen-to-twenty minutes. Subsequent topical application of L-arginine utilizes its topical or systemic effect, via the NOS synthase/NO system, to create corpus cavernosa engorgement, which has a delayed onset of action from between

fifteen to twenty minutes By combining the two compounds, with simultaneous topical application of menthol and L-arginine, their effect would be immediate and prolonged because of their two different, but related, methods of action.

L-arginine absorption is promoted by the actions of menthol. Eccles reports studies by Katayama (1972), Morimoto (1993) and Yamo (1991) where the topical application of menthol, because of its local vasodilatative and lipidphillic properties, promotes the penetration of other topical drug preparation applied concurrently with menthol. These studies found rapid absorption of indomethacin, cortisone, morphine hydrochloride, and methyl salicylate when applied topically in combination with menthol. It is only rational that the absorption of L-arginine by the mucous membrane is hastened when applied in combination with menthol. This is a direct action of the lipidphillic and vasodilation properties of menthol. The action of menthol causes the L-arginine NOS/NO vasodilation to be effective within minutes of the topical application of the menthol/L-arginine combination.

A different effect is realized on the clitoris and the penis using the same menthol/L-arginine combination. This is because the integument of the

90

clitoris is non-keratinized epithelium, a 1% menthol and 2% L-arginine preparation, topically applied, is immediately absorbed, and immediately active in sensitizing the clitoris. The penis is relatively unaffected by the application of the same strength cream because the external epithelium is keratinized squamous epithelium. The keratinized squamous epithelium, by nature of the keratin, acts as a barrier to the absorption of the preparation. Therefore, the same preparation of 1% menthol and 2% L-arginine combination sensitizes the clitoris, without sensitizing the penis. Such a combination cream may be carried in &/or on and applied by the applicators as described in the aforementioned co-pending U.S. Patent Applications serial numbers 09/414,250 and 09/349,227, each being incorporated herein by reference.

The invention thus comprises a topical compound preparation of sensitizing cream for application to the non-keratinized epithelium of a female, comprising a preparation of L-arginine, and a preparation of menthol. The preparation of L-arginine may have a concentration of 4% or less. The preparation of menthol may have a concentration of 5% or less. The preparation of L-arginine may in one embodiment have a concentration of 2% and the preparation of menthol may have a concentration of 1%.

75
91

The compound preparation may in one embodiment be enclosed within a reservoir of an applicator. The reservoir may have multiple chambers. The reservoir may have an arrangement of conduits from the reservoir to an outer clitoral-touching surface on the applicator. The invention also includes a method of sensitizing the non-keratinized epithelium of a female, comprising the steps of: applying a preparation of menthol and L-arginine to the epithelium, arranging the preparation of L-arginine in a concentration of less than 4%; and arranging the preparation of menthol in a concentration of less than 5%. The method may include the step of: placing the preparations of menthol and L-arginine in an applicator reservoir for distribution onto the epithelium, and may include the step of applying the preparations to the epithelium in a sequential manner.

09469959.122199

Brief Description of the Drawing

The objects and advantages of the present invention will become more apparent when viewed in conjunction with the following drawing, in which:

Figure 1 is a perspective view of an applicator for the application of the preparation of the present invention.

96
92

Description of the Preferred Embodiments

The present invention utilizes the unique properties of a combination menthol/L-arginine topical clitoral sensitizing preparation. In one embodiment, a sequential application first by menthol applied topically to the mucous membrane of the clitoris has an almost immediate response by affecting vasodilation and blood engorgement warmth (via the thermoreceptors). The duration of menthol's action on mucous membranes may be for fifteen-to-twenty minutes. Subsequent topical application of L-arginine utilizes its topical or systemic effect, via the NOS synthase/NO system, to create corpus cavernosa engorgement, which has a delayed onset of action from between fifteen to twenty minutes. Such a sequential delivery of multiple preparations may be accomplished by an applicator 10, as shown in figure 1. The applicator 10 may have a plurality of reservoirs 12 and 14, each with their own conduits 16 and 18 between the reservoirs 12 and 14 and a clitoral engaging surface 20. Each preparation of menthol and L-arginine may have their own rate of distribution, to provide the sequential application to the treatment situs.

0946995 - 122199

97
93

In a further embodiment, a common reservoir 22 may be arranged within the applicator 10. By combining the two compounds within that common reservoir 22 as a simultaneous topical application of menthol and L-arginine together, their effect would be immediate and prolonged because of their two different, but related, methods of action. Such a range of L-arginine of less than 4% concentration and a range of menthol of less than 5% concentration is preferred in an application, either with the distribution via an applicator 10, or by other topical application.

09469959.122199

28
94

I claim:

1. A topical compound preparation of sensitizing cream for application to the non-keratinized epithelium of a female, comprising:

a preparation of L-arginine; and

a preparation of menthol.
2. The topical compound preparation of sensitizing cream for application to the non-keratinized epithelium of a female, as recited in claim 1, wherein said preparation of L-arginine has a concentration of 4% or less.
3. The topical compound preparation of sensitizing cream for application to the non-keratinized epithelium of a female, as recited in claim 1, wherein said preparation of menthol has a concentration of 5% or less.
4. The topical compound preparation of sensitizing cream for application to the non-keratinized epithelium of a female, as recited in claim 1, wherein said preparation of L-arginine has a concentration of 2% and said preparation of menthol has a concentration of 1%.

094
959-122199

98
95

5. The topical compound preparation of sensitizing cream for application to the non-keratinized epithelium of a female, as recited in claim 1, wherein said compound preparation is enclosed within a reservoir of an applicator.
6. The topical compound preparation of sensitizing cream for application to the non-keratinized epithelium of a female, as recited in claim 5, wherein said reservoir has multiple chambers.
7. The topical compound preparation of sensitizing cream for application to the non-keratinized epithelium of a female, as recited in claim 5, wherein said reservoir has an arrangement of conduits from said reservoir to an outer clitoral touching surface on said applicator.
8. A method of sensitizing the non-keratinized epithelium of a female, comprising the steps of:

 applying a preparation of menthol and L-arginine to said epithelium.

094 9959-122199

160
96

9. A method of sensitizing the non-keratinized epithelium of a female, as recited in claim 8, comprising the steps of:

arranging said preparation of L-arginine in a concentration of less than 4%; and

arranging said preparation of menthol in a concentration of less than 5%.

10. The method of sensitizing the non-keratinized epithelium of a female, as recited in claim 8, comprising the step of:

placing said preparations of menthol and L-arginine in an applicator reservoir for distribution onto said epithelium.

11. The method of sensitizing the non-keratinized epithelium of a female, as recited in claim 8, comprising the steps of:

applying said preparations to the epithelium in a sequential manner.

4
959-122199

101-
97

Abstract of the Disclosure

The invention comprises a topical compound preparation of sensitizing cream for application to the non-keratinized epithelium of a female, comprising a preparation of L-arginine and a preparation of menthol. The preparation of L-arginine may have a concentration of 4% or less, and the preparation of menthol has a concentration of 5% or less.

09469959 . 122199

102
98




FIG 1

0 469959 .122199 661221 656594 0

40 JIS/LK
00.097.103
107
99

TRADUCCION OFICIAL NO. 007-2001
DE UN DOCUMENTO ESCRITO EN INGLES

ESTADOS UNIDOS DE AMÉRICA

**A TODOS AQUELLOS QUE LLEGAREN A LEER EL CONTENIDO DE ESTE
DOCUMENTO**

DEPARTAMENTO DE COMERCIO DE LOS ESTADOS UNIDOS

Oficina de Marcas y Patentes de los Estados Unidos

Enero 3 de 2001

Mediante este documento se certifica que anexo al presente se encuentra una fiel copia de los Registros de la Oficina de Marcas y Patentes de los Estados Unidos de América correspondientes a la solicitud de patente abajo identificada la cual cumpla con los requerimientos exigidos para el otorgamiento de una fecha de presentación de conformidad con lo dispuesto en la Sección 35 USC 111

Número de Solicitud: 09/520.110

Fecha de Presentación: Marzo 7 de 2000

Por autoridad del

COMISIONADO DE MARCAS Y PATENTES

Angela A. Polecio
ANGELA A. POLECIO
Traductor e Intérprete Oficial
Resol. No. 0177 del/97 MinJusticia

P.R. GRANT

Funcionario Encargado de Certificaciones (Firma y Sello)

Sello JC377 U S PTO (Oficina de Marcas y Patentes)

(Codigo de Barras)

03/07/00

Sello JC678 U S PTO (Oficina de Marcas y Patentes)

09/520110

(Codigo de Barras)

03/07/00

Expediente de Practicante No. Thompson-4

PATENTE

EN LA OFICINA DE MARCAS Y PATENTES DE ESTADOS UNIDOS

Solicitud de Patente

Comisionado Asistente para Patentes

Washington, D C 20231

TRANSMISION DE NUEVA SOLICITUD

Por el presente se transmite para presentación la solicitud de patente del (los)

inventor(es) **THOMPSON, R.**

Advertencia: La sección 37 CFR 1 41(a)(1) señala

Angela A. Pulecio Mayorga
ANGELA A. PULECIO MAYORGA
Traductor e Intérprete Oficial
Resol. No. 0177 del/97 MinJusticia

106
101

(a) Las patentes son solicitadas a nombre o nombres de su actual o actuales inventor(es)

(1) La titularidad de invención de una solicitud no provisional es aquella titularidad de invención establecida en el juramento o declaración como se establece en 1 63, a excepción de lo previsto por 1 53(d)(4) y 1 63(d). Si un juramento o declaración de conformidad con 1 63 no es presentado mientras este pendiente una solicitud no provisional, la titularidad de invención será aquella establecida en los documentos de solicitud presentados de conformidad con 1 53(b) a menos que se presente una petición bajo este párrafo acompañado por la tasa establecida en 1 17(i) en donde se suministre o cambie el nombre o nombres del inventor o inventores

Para (Titulo) **Compuestos Expandidos de Sensibilización del clítoris con Métodos y Aparatos para la colocación de estos compuestos**

CERTIFICACION BAJO LA SECCION 37 CFR 1.10*

(El número de etiqueta del Correo Expreso es obligatorio)

(La certificación del Correo Expreso es opcional)

Por el presente certifico que esta Transmisión de Nueva Solicitud y los documentos referidos como los anexos de aquella están siendo depositados en el Servicio Postal de los Estados Unidos este 7 de Marzo de 2000 en un sobre como "Oficina Postal de Correo Expreso para el destinatario", Numero de Envío EE32769621705, dirigido al Comisionado Asistente para Patentes, Washington D C 20231

(D N Halgrek


ANGELA A. PULECIO MAYORGA
Traductor e Intérprete Oficial
Resol No 0177 del/97 MinJusticia

(escribir nombre de persona que envia documento)

(Firma) _____

(Firma de persona que envía documento)

Advertencia: Los procedimientos de Certificado de envío (primera clase) o transmisión de fax según la Sección 37 CFR 1.8 no pueden ser usados para obtener una fecha de envío o transmisión para esta correspondencia

Advertencia: Cada documento o tasa presentados por "Correo Expreso" deberá contener el número de la etiqueta de envío de "Correo Expreso" colocado antes del envío Sección 37 CFR 1.10(b)

"Teniendo en cuenta que la presentación de correspondencia bajo la Sección 1.10 que no tenga fijada la etiqueta de envío de Correo Expreso es una omisión que se puede evitar con el cuidado razonable, las solicitudes de renuncia a este requerimiento no serán concedidas bajo petición" Aviso de Oct 24 de 1996, 60 Reg Fed 56 439 a 56 442

1. Tipo de Solicitud

Este solicitud consiste en un(a)

(indicar abajo un asunto aplicable)


 X Original (no provisional)

 Diseño

 Planta

ADVERTENCIA: No usar esta transmisión para el cumplimiento en E U de una

Solicitud Internacional bajo la Sección 35 U.S.C. 371(a)(4), a menos


ANGELA A. POLECIO MAYORGA
Traductor e Intérprete Oficial
Resol. No. 0177 del/97 MinJusticia

103

*que la Solicitud Internacional esté siendo presentada como una
solicitud de división, de continuacion o continuación en parte*

ADVERTENCIA: *No usar esta transmisión para la presentación de una solicitud
provisional*

NOTA *Si se aplica alguno de los siguientes 3 puntos, complete y adjunte LAS
PAGINAS PARA UNA NUEVA TRANSMISION DE SOLICITUD DONDE
HAYA UN BENEFICIO DE REIVINDICACION DE UNA SOLICITUD
ESTADOUNIDENSE ANTERIOR y una NOTIFICACION EN LA SOLICITUD
MATRIZ DE LA PRESENTACION DE ESTA SOLICITUD DE
CONTINUACION*

☐ De división

☐ Continuación

☒ Continuacion en parte (C-E-P)

- 2 **Beneficio de una(s) Solicitud(es) Estadounidense(s) anterior(es)** (35 U S C
1993(e) 120, o 121)
(EN BLANCO)

3. **Documentos Anexos:**

A Se requiere para la fecha de presentación de la Solicitud bajo la Sección 37 CFR

1 53(b) (Regular) o 37 CFR 1 153 (Diseño)

14 Paginas de especificaciones


ANGELA A. PULECIO MAYORGA
Traductor é Interprete Oficial
Resol. No 0177 del/97 MinJusticia

5 Paginas de reivindicaciones

2 Paginas de dibujos

108
104

ADVERTENCIA: NO enviar dibujos originales Al presentar una solicitud de patente se debe presentar una copia de alta calidad de los dibujos Los dibujos que son enviados a la Oficina deben encontrarse en un papel fuerte blanco, liso y no brillante y deben cumplir con los estandares de acuerdo con 1 84 Si es necesario hacer correcciones a los dibujos, deberán hacerse sobre el original y luego debera enviarse a la Oficina una copia de alta calidad del original corregido Solo se requiere de una copia Para comentarios en lo propuesto por aquella Sección 37 CFR 1 84, ver Aviso de Marzo 9, 1988 (1990 O G 57-62)

NOTA Indicios de identificación, si son suministrados, deberán incluir el numero de solicitud o el título de la invencion, el nombre del inventor, el número de expediente (si existe), y el número y teléfono de una persona para ser llamada en caso de que la Oficina no pueda ajustar los dibujos a la solicitud adecuada Esta información debe ser colocada en la parte trasera de la hoja del dibujo a una distancia mínima de 1 5 cm (5/8 pulgadas) hacia abajo desde la parte superior de la hoja " 37 CFR 1 84 (c))

(completar lo siguiente, si es aplicable)


ANGELA A PULECIO MAYORGA
Traductor é Intérprete Oficial
Resol No 0177 del/97 MinJusticia

#0
105

- ☐ El (los) dibujo(s) anexo(s) es o son fotografía(s), y también se anexa una "SOLICITUD PARA ACEPTAR FOTOGRAFIA(S), COMO DIBUJO(S)" 37 CFR 1 84(b)
- ☐ Formal
- ☒ Informal

B Otros documentos que se anexan

- ☐ Páginas de declaración y poder de abogado
- ☒ 1 Páginas de extracto
- ☐ Otros

4. Documentos adicionales anexos

(EN BLANCO)

5. Declaración o juramento (incluye poder)

NOTA En las solicitudes de continuación o división no se requiere de una declaración nueva, teniendo en cuenta que la solicitud no provisional anterior contenía la declaración requerida, la solicitud a presentarse es por todos o algunos de los inventores nombrados en la solicitud anterior, no hay asuntos nuevos en la solicitud a presentarse, y además se presenta una copia de la declaración firmada que se presentó en la solicitud anterior (que muestre la firma o una indicación en ella de que ha sido firmada) La copia debe estar acompañada de una declaración solicitando la eliminación de los nombres de la(s) persona(s) que no sean inventores de la solicitud a presentarse Si la declaración en la solicitud anterior fue presentada bajo 1 47, entonces se deberá presentar una copia de esa declaración


ANGELA A. PULECIO MAYORGA
Traductor e Interpreté Oficial
Resol. No 0177 del/97 MinJusticia

106

acompañada de una copia de la decisión que le concedió el estado 1 47 o si una persona que no ha firmado bajo la sección 1 47 se ha unido con posterioridad en una solicitud anterior, entonces deberá presentarse una copia de la declaración posterior firmada Ver 37 CFR Sección 1 63 (d)(1)-(3)

NOTA Una declaración presentada para completar una solicitud deberá encontrarse firmada, identificar la especificación respecto de la cual se dirige, identificar a cada inventor con su nombre completo incluyendo el apellido y al menos un nombre, sin abreviación junto con cualquier otro nombre o inicial, así como la residencia, dirección postal y país o ciudadanía de cada inventor, y declarar si el inventor es único o conjunto 37 C F R Sección 1 63 (a)(1)-(4)

_____ Se anexa

Firmado por

(marcar todas las casillas aplicables)

_____ Inventor(es)
_____ Representante legal del inventor(es)

37 CFR 1 42 o 1 43

_____ Inventor conjunto o persona que demuestre una titularidad a nombre del inventor que se negó a firmar o que no pudo ser localizado


ANGELA A. PULECIO MAYOREÁ
Traductor e Intérprete Oficial
Resol. No. 0177 del/97 MinJusticia

_____ Esta es la petición requerida por 37 CFR 1 47 y la
declaración requerida por 37 CFR 1 47 también se adjunta
Ver punto 13 más abajo para la tasa

X No se Anexa

NOTA Donde la presentación sea en cumplimiento en los E U de una Solicitud Internacional o donde el cumplimiento de la solicitud Estadounidense contenga asuntos adicionales a la solicitud Internacional, la solicitud podrá ser tratada como una continuación o continuación en parte, según sea el caso, mediante el uso de PAGINAS ADICIONALES PARA LA TRANSMISION DE UNA NUEVA SOLICITUD DONDE SE REIVINDIQUE EL BENEFICIO DE LA PRIORIDAD DE LA SOLICITUD ESTADOUNIDENSE

_____ La solicitud es hecha por una persona autorizada según la Sección 37
CFR 1 41 (c) a nombre de *todos* los inventores antes mencionados

*(La declaración o juramento, junto con la sobretasa requerida por la Sección 37
CFR 1 16(e) pueden presentarse con posterioridad)*

_____ Demostración de que la presentación fue autorizada
(no es necesario a menos que sea requerida 37 CFR 1 41(d))

6. Declaración de Titularidad de invención

Angela Pulcio
ANGELA A PULCIO MAYORGA
Traductor e Int. Oficial
Resol No 0177 del 97 MinJusticia

113
108

ADVERTENCIA: Si los inventores mencionados no son cada uno de los inventores de todas las reivindicaciones, deberá remitiarse una explicación, incluyendo la titularidad de las varias reivindicaciones al momento en que fue hecha la última reivindicación.

La titularidad de invención de todas las reivindicaciones en esta solicitud son

☒ **Iguales**

O

☐ **No son iguales** Se realizó una explicación, incluyendo la titularidad de las varias reivindicaciones al momento en que fue hecha la última reivindicación

☐ **Se presenta**

☐ **No se presenta**

7. Idioma

NOTA Se puede presentar una solicitud en idioma diferente al inglés incluyendo un juramento o declaración firmado. Se requiere presentar una traducción al inglés de la solicitud en otro idioma y la tasa de procesamiento de \$130.00 ordenado por 37 CFR 1.17(k), al momento de presentación de la solicitud o cuando la Oficina lo requiera 37 CFR 1.52(d)

☒ **Inglés**

☐ **Otro Idioma**

☐ **La traducción adjunta incluye una declaración de que la traducción es exacta 37 CFR 1.52(d)**


ANGELA A. PULECIO MAYORGA
Traductor e Intérprete Oficial
Resol. No. 0177 del/97 Minjusticia

8. Cesión

X Una cesión de la invención a 40J'S

___ se anexa También se anexa una ___ "CARATULA DE CESION (DOCUMENTO) QUE ACOMPAÑA LA NUEVA SOLICITUD DE PATENTE" o ___ FORMULARIO DE LA OMP 1595

X Se presentará próximamente

NOTA Si se presenta una cesión con una solicitud nueva, enviar dos cartas separadas, una para la solicitud y otra para la cesión' Aviso de Mayo 4 1990 (1114 O G 77-78)

ADVERTENCIA: Debe presentarse un nuevo "CERTIFICADO BAJO LA SECCION 37 CFR 3 73 (b)" debidamente firmado cuando se presenta por parte del cesionario una solicitud de continuación en parte Aviso de 30 de Abril de 1993, 1150 O G 62-64

9. Copia Certificada

(EN BLANCO)

10 Cálculo de Tasa (37 CFR 1 16)


ANGELATA PULACIO MAYORGA
Traductor e Intérprete Oficial
Resol No. 0177 del/87 MinJusticia

A. X Solicitud Normal

REIVINDICACIONES SEGÚN PRESENTACION

HS
110

Número presentado	Número Extra	Tasa	Tarifa Básica
			37 CFR 1 16 (a)
			\$660 00
Total			
Reivindicaciones			
(37 CFR 1 16(c)) 70-20=	x	\$22 00	
Reivindicaciones			
Independientes			
(37 CFR 1 16 (b)) 2-3 =	x	\$82 00	
Reivindicaciones			
Dependientes			
Múltiples			
Si hay(37 CFR 1 16(d))	+	\$270 00	

Angela V. Pulecio
ANGELA V. PULECIO MAYORGA
Traductor e Interpreté oficial
Resol No 0177 del/97 MinJusticia

- ___ Se adjunta corrección cancelando reivindicaciones adicionales
- ___ Se anexa corrección eliminando dependencias múltiples
- ___ No se pagaran en este momento tasas para reivindicaciones adicionales

46
111

NOTA Si las tasas por reivindicaciones no son pagadas al momento de la presentación deberán ser pagadas o de lo contrario las reivindicaciones serán canceladas por la corrección, antes de la expiración del período establecido para respuesta por la Oficina de marcas y Patentes en cualquier aviso de incumplimiento de tasas 37 CFR 1 16 (d)

Cálculo de Tasa de Presentación \$660 00

B. Solicitud de Diseño

(EN BLANCO)

C. Solicitud de Planta

(EN BLANCO)

11 Declaración de Pequeña Entidad

— Se está presentando declaración(es) de que este documento es presentado por una pequeña entidad bajo la sección 37 CFR 1 9 y 1 27

(completar lo siguiente si es aplicable)

X La calidad de pequeña entidad fue reivindicada en la solicitud anterior

09/340 227 presentada el 7 de Julio de 1999 respecto de la cual se reivindica beneficio para esta solicitud bajo la

Sección 35 U S C — 119(e)

Angela Pulido
ANGELA M. PULIDO MAYANGA
Traductor e Interpreté Oficial
Resol. No. 0177 del/57 MinJusticia

117
112

X 120

 121

 365(c)

y respecto de la cual todavía la calidad de pequeña entidad todavía se desea
y es apropiado tenerla

 Se incluye una copia de la declaración

Cálculo de la Tasa de Presentación (50% de A, B, o C arriba)

\$385 00

NOTA Cualquier exceso de la tasa completa pagada será reembolsada si se establece el estado de pequeña entidad y si se presenta una solicitud de reembolso dentro de los 2 meses desde la fecha del pago en tiempo de la tasa completa El término de dos meses no es extensible bajo 1 136 37 CFR 1 28(a).

12. **Solicitud para Búsqueda de Tipo Internacional (37 CFR 1.104 (d))**

(EN BLANCO)

13. **Pago de Tasas Canceladas en Este Momento**

X No se adjunta

X No es necesario pagar tasas de presentación a este momento

(Esta y la sobretasa ordenada por la Sección 37 CFR 1 16(e) pueden pagarse posteriormente)

Angela Pulido
ANGELA A. PULIDO MAYORGA
Traductor e Intérprete Oficial
Resol. No. 0177 del 9/91 Injusticia

118
113

___ Se adjunta (EN BLANCO)

14. Método de Pago de Tasas

(EN BLANCO)

15. Autorización para Cargar Tasas Adicionales

(EN BLANCO)

16. Instrucciones para Sobre pago

NOTA ' Las cantidades equivalentes a veinticinco dólares o menos no serán reembolsadas a menos que se solicite específicamente dentro de un termino razonable, ni el pagador será notificado de tales cantidades, cantidades mayores a veinticinco dólares serán reembolsadas mediante cheque o, si se solicita mediante consignación en una cuenta" 37 CFR Sección 1 26(a)

___ No de Cuenta _____

X Reembolso

Reg No 27056

(Firma) _____

FIRMA DEL PRACTICANTE

Tel No (978) 526-8000

Donald N. Halgren


ANGELA A. PULECIO MAYOREÁ
Traductor e Intérprete Oficial
Resol. No. 0177 del/97 MinJusticia

(escribir nombre del Abogado)

119
114

No Cliente

35 Central Street

Dirección Postal

Manchester MA 01944


ANGELA A. PULECIO MAYORCA
Traductor e Intérprete Oficial
Resol No. 0177 del/97 MinJusticia

120
115

X

Incorporación por referencia de páginas adicionales

(marcar el siguiente punto si la solicitud en esta transmisión reivindica el beneficio de una(s) solicitud(es) estadounidense(s) anterior(es) (incluyendo una solicitud internacional incluyendo el estado de E U como una solicitud de continuación, división o C-E-P) y completar y adjuntar las PAGINAS ADICIONALES PARA LA TRANSMISIÓN DE SOLICITUD NUEVA DONDE SE REIVINDIQUE EL BENEFICIO DE SOLICITUD(ES) ESTADOUNIDENSE(S) ANTERIORES

X

Más las Páginas Adicionales por la transmisión de Solicitud Nueva donde se reivindique el Beneficio de Solicitud(es) Estadounidense(s) anterior(es)

Número de Páginas adicionales 5

Declaración donde no se adjuntan páginas adicionales

(EN BLANCO)


ANGELA A. PULECIO MAYORGA
Traductor e Intérprete Oficial
Resol No. 0177 del/97 MinJusticia

**PAGINAS ADICIONALES PARA TRANSMISION DE SOLICITUD DONDE SE
REIVINDICA EL BENEFICIO DE SOLICITUD(ES) ESTADOUNIDENSE(S)
ANTERIOR(ES)**

NOTA Ver 37 CFR Seccion 1 78

17. Relacionado Anteriormente

ADVERTENCIA: Si una solicitud reivindica el beneficio de la fecha de presentacion de una solicitud presentada con anterioridad bajo la Seccion 35 U.S.C 120, 121 o 365(c), el término de 20 años de esa solicitud se fundamentará en la fecha de presentación de la solicitud Estadounidense anterior a la cual se refiere la solicitud bajo la Sección 35 U.S.C 120,121 o 365 (c) La sección 35 U S C 154(a)(2) no tiene en cuenta, para la determinación del término de la patente, aquellas solicitudes donde la prioridad sea reclamada bajo la Sección 35 U.S.C 119, 365(a) o 365(b) Para una solicitud c-e-p, el solicitante deberá revisar si cualquier reivindicación en la patente a concederse está fundamentada en una solicitud anterior y, si no, el solicitante deberá considerar la cancelacion de la referencia a esa solicitud presentada con anterioridad El término de una patente no se fundamenta en ninguna aproximación de reivindicación por

reivindicación Ver Aviso de Abril 14 de 1995, 60 Reg Fed 20 195
a 20 205

117

(completar lo siguiente, si es aplicable)

X Enmendar la especificación mediante la inclusión antes de la primera línea
de la siguiente frase

A.35 U.S.C. Sección 119(e)

(EN BLANCO)

B. 35 U.S.C. Sección 120, 121 y 365(e)

X Esta solicitud es una
_____ continuación
X continuación en parte
_____ división

de solicitudes pendientes simultáneamente

X solicitud número 09 340 227 presentada en Julio 7 de 1999

_____ Solicitud Internacional _____ presentada en _____
_____ la cual designó los E U

(A CONTINUACION EN BLANCO)

Angela Pulido Mayorga
ANGELA M. PULIDO MAYORGA
Traductor e Intérprete Judicial
Resol. No. 0177 del 97 MinJusticia

18. **Relacionado Anteriormente – Sección 35 U.S.C Sección 119 Reivindicación de
Prioridad por Solicitud Anterior**

(EN BLANCO)

19. **Mantenimiento de Codependencia de Solicitud Anterior**

(EN BLANCO)

20. **Declaración Adicional de Titularidad de invención donde se reivindica el
Beneficio de Solicitud(es) Anterior(es)**

(completar asunto aplicable de (a), (b) o (c))

- (a) Esta solicitud muestra y reivindica solo un asunto del presentado en la solicitud anterior cuyas particularidades se encuentran indicadas arriba y el o los inventores en esta solicitud son
- los mismos
- menos que aquellos indicados en la solicitud anterior Se solicita que el siguiente inventor identificado en la solicitud anterior sea eliminado
- _____

- (b) X Esta solicitud muestra y reivindica muestras adicionales mediante enmiendas y se presentará una nueva declaración o juramento Con relación a la solicitud anterior, el (los) inventor(es) en esta solicitud son

129
119

X los mismos

_____ los siguientes inventores adicionales se han adicionado

(c) La titularidad de invención de todas las reivindicaciones en esta solicitud son

X las mismas

_____ no las mismas Una explicación, que incluye la titularidad de las diversas reivindicaciones al momento en que la última invención fue reivindicada,

_____ se anexa

_____ será anexada

21. Abandono de Solicitud Anterior (si es aplicable)

(EN BLANCO)

22. Petición para Suspensión de ejecución del Tiempo Necesario para Presentar Enmiendas

(EN BLANCO)

23. Pequeña Entidad (38 C F R Sección 1 28 (a))

X El solicitante ha establecido la calidad de pequeña entidad mediante la presentación de una declaración en la solicitud matriz No 09/340 227 el 7 de Julio de 1999

_____ Se incluye una copia de la declaración previamente presentada


ANGELA M. PULECIO MAYORGA
Traductor e Intérprete oficial
Resol No 0177 del/97 MinJusticia

123
120

ADVERTENCIA: Ver Sección 37 CFR 1 28(a)

ADVERTENCIA: *"La calidad de pequeña entidad no podrá establecerse cuando una persona o personas que firmen la declaración puedan inequívocamente hacer la auto certificación requerida" M P E P 509 03, 6ta edición, rev 2, Julio 1996 (énfasis agregado)*

24. NOTIFICACION EN SOLICITUD MATRIZ DE ESTA PRESENTACIÓN

(EN BLANCO)


ANGELA A. PULECIO MAYORGA
Traductor e Intérprete Oficial
Resol No. 0177 del/97 MinJusticia

Yo reivindico

126
121

- 1 Un aplicador de manipulación manual para la aplicación de un estimulante del clitoris para ser usado en la aplicación de un compuesto estimulante del clitoris en el area del clitoris del cuerpo humano femenino, que comprende
un compartimiento para contener un compuesto estimulante del clitoris,
un compuesto estimulante del clitoris dentro de dicho compartimiento, y
un protector removible sobre dicho compartimiento para desplegar dicho compuesto lo cual permite que dicho compuesto sea aplicado topicamente
- 2 El aplicador de manipulacion manual para la aplicación de un estimulante del clitoris como se indica en la reivindicación 1, donde dicho protector comprende una tapa removible
- 3 El aplicador de manipulación manual para la aplicación de un estimulante del clitoris como se indica en la reivindicación 1, donde el compartimiento comprende un tubo y dicho protector
- 4 El aplicador de manipulación manual para la aplicación de un estimulante del clitoris como se indica en la reivindicación 1, donde dicho compuesto comprende un gel


ANGELA AL PULECIO MAYORBA
Traductor e Interpret: Oficial
Resol. No. 0177 del/97 MinJusticia

- 127
122
- 5 El aplicador de manipulación manual para la aplicación de un estimulante del clitoris como se indica en la reivindicación 1, donde dicho compuesto comprende una crema
 - 6 El aplicador de manipulación manual para la aplicación de un estimulante del clitoris como se indica en la reivindicación 1, donde dicho compuesto comprende un líquido fluido
 - 7 El aplicador de manipulación manual para la aplicación de un estimulante del clitoris como se indica en la reivindicación 1, donde dicho compuesto comprende un semi-sólido
 - 8 El aplicador de manipulación manual para la aplicación de un estimulante del clitoris como se indica en la reivindicación 7, donde dicho compuesto semi-sólido tiene una ranura en su extremo más lejano que facilita la aplicación de dicho compuesto
 - 9 El aplicador de manipulación manual para la aplicación de un estimulante del clitoris como se indica en la reivindicación 6, donde dicho aplicador incluye un cepillo colocado sobre éste
 - 10 El aplicador de manipulación manual para la aplicación de un estimulante del clitoris como se indica en la reivindicación 6, donde dicho aplicador incluye una esponja colocada sobre éste

- 11 El aplicador de manipulación manual para la aplicación de un estimulante del clitoris como se indica en la reivindicación 6, donde dicho aplicador incluye un dispositivo de bola rodante colocado sobre éste
- 12 El aplicador de manipulación manual para la aplicación de un estimulante del clitoris como se indica en la reivindicación 1, donde dicho compuesto comprende una mezcla de mentol y L-arginina.
- 13 El aplicador de manipulación manual para la aplicación de un estimulante del clitoris como se indica en la reivindicación 1, donde dicho compuesto tiene componentes seleccionados del grupo consistente en aceite de menta suave, aceite de menta, aceite de eucalipto, aceite de toronjil, aceite de trementina de la India, aceite de alcanfor y aceites de canela
- 14 El aplicador de manipulación manual para la aplicación de un estimulante del clitoris como se indica en la reivindicación 1, donde dicho compuesto tiene componentes seleccionados del grupo consistente en Salicilato, capsiacina, y vitaminas solubles en aceite (co-enzimas) A, D o E
- 15 Un método de sensibilización del clitoris del cuerpo humano femenino, que comprende los siguientes pasos

aplicación de un compuesto de un agente sensibilizador de dicho clitoris, y

129
124

seleccion de un compuesto de dicho agente sensibilizador del grupo consistente en aceite de menta suave, aceite de menta, aceite de eucalipto, aceite de toronjil, aceite de trementina de la India, aceite de alcanfor, aceites de canela, Salicilato capsicacina, y vitaminas solubles en aceite (co-enzimas) A, D o E

- 16 El método de sensibilización del clítoris del cuerpo humano femenino, como se indica en la reivindicación 15, que comprende los siguientes pasos

colocación de dicho agente sensibilizador en el compartimiento de un aplicador,

disposicion de un protector sobre dicho aplicador para proteger dicho agente en dicho compartimiento

- 17 El método de sensibilización del clítoris del cuerpo humano femenino como se indica en la reivindicación 15, donde dicho aplicador incluye un cepillo

- 18 El método de sensibilización del clítoris del cuerpo humano femenino, como se indica en la reivindicación 15, donde dicho aplicador incluye un rodillo a un extremo de éste

- 19 El metodo de sensibilización del clítoris del cuerpo humano femenino, como se indica en la reivindicación 15, donde dicho aplicador incluye una esponja a un extremo de este


ANGELA A. PULECIO MAYORGA
Traductor e Int. Oficial
Resol. No. 0177 del 97 Minjusticia

- 20 El método de sensibilización del clítoris del cuerpo humano femenino, como se indica en la reivindicación 15, donde el agente sensibilizador comprende una barra semi-sólida que contiene una ranura en forma de "V" en el extremo más distante de ésta para facilitar la aplicación de dicho agente en el clítoris

Angela A. Pulecio
ANGELA A. PULECIO MAYORSA
Traductor e Inter. Oficial
Resol No 0177 del 15/1 MinJusticia

Resumen de la Invención

131
126

La presente invención comprende un método y aparato consistente en un aplicador de manipulación manual para la aplicación de un estimulante del clitoris, para ser usado en la aplicación de un compuesto estimulante del clitoris en el area del clitoris del cuerpo humano femenino. En el aparato se encuentra dispuesto un compartimiento que contiene el compuesto estimulante del clitoris, junto con el compuesto estimulante del clitoris el cual está contenido en dicho compartimiento. Sobre el compartimiento se encuentra dispuesto un protector removible para desplegar dicho compuesto, lo cual permite que dicho compuesto sea aplicado tópicamente.

Es traducción fiel de la cual queda copia en el archivo del Traductor para su confrontación, a la cual me remito.

Bogotá, D.C. 29 de Enero de 2001


ANGELA A. PULECIO MAYORGA
Traductor e Interpretación Oficial
Resol. No. 0177 del 27 de Minjusticia

00 097103

133

127

PA 345698



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

January 03, 2001

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 09/520,110

FILING DATE: March 07, 2000



By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

P. R. Grant

P. R. GRANT

Certifying Officer

3-8-00

A

127
128

Practitioner's Docket No. Thompson-4

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of
Inventor(s). THOMPSON, R.

WARNING: 37 C.F.R. § 1.41(a)(1) points out:

"(a) A patent is applied for in the name or names of the actual inventor or inventors.

"(1) The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by § 1.63, except as provided for in § 1.63(a)(4) and § 1.63(a). If an oath or declaration as prescribed by § 1.63 is not filed during the pendency of a nonprovisional application, the inventorship is that inventorship set forth in the application papers filed pursuant to § 1.53(b), unless a petition under this paragraph accompanied by the fee set forth in § 1.170 is filed supplying or changing the name or names of the inventor or inventors."

For (title):

Expanded Clitoral Sensitizing Compounds with
Methods and Apparatus for the Delivery of these
Compounds

CERTIFICATION UNDER 37 C.F.R. 1.10*
(Express Mail label number is mandatory)
(Express Mail certification is optional.)

I hereby certify that this New Application Transmittal and the documents referred to as attached therein are being deposited with the United States Postal Service on this date 7 March 2000 in an envelope as "Express Mail Post Office to Addressee," mailing Label Number 327696419, addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

D. N. Halgren
(type or print name of person mailing paper)

[Signature]
Signature of person mailing paper

WARNING: Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(a).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,436, at 56,442.

(Application Transmittal [4-1]—page 1 of 11)

1c377 U.S. PRO
03/07/00

1c377 U.S. PRO
09/520110
03/07/00

00520110-030700

1. Type of Application

This new application is for a(n)

(check one applicable item below)

- ☒ Original (nonprovisional)
☐ Design
☐ Plant

WARNING: Do not use this transmittal for a completion in the U.S. of an International Application under 35 U.S.C. 371(c)(4), unless the International Application is being filed as a divisional, continuation or continuation-in-part application.

WARNING: Do not use this transmittal for the filing of a provisional application.

NOTE: If one of the following 3 items apply, then complete and attach **ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF A PRIOR U.S. APPLICATION CLAIMED** and a **NOTIFICATION IN PARENT APPLICATION OF THE FILING OF THIS CONTINUATION APPLICATION**.

- ☐ Divisional.
☐ Continuation.
☒ Continuation-in-part (C-I-P).

2. Benefit of Prior U.S. Application(s) (35 U.S.C. 119(a), 120, or 121)

NOTE: A nonprovisional application may claim an invention disclosed in one or more prior filed/cpending nonprovisional applications or expending international applications designating the United States of America. In order for a nonprovisional application to claim the benefit of a prior filed expending nonprovisional application or expending international application designating the United States of America, each prior application must name as an inventor at least one inventor named in the later filed nonprovisional application and disclose the named inventor's invention claimed in at least one claim of the later filed nonprovisional application in the manner provided by the first paragraph of 35 U.S.C. 112. Each prior application must also be:

(i) An international application entitled to a filing date in accordance with PCT Article 11 and designating the United States of America; or

(ii) Complete as set forth in § 1.51(b); or

(iii) Entitled to a filing date as set forth in § 1.53(b) or § 1.53(d) and include the basic filing fee set forth in § 1.16; or

(iv) Entitled to a filing date as set forth in § 1.53(b) and have paid therein the processing and retention fee set forth in § 1.21(f) within the time period set forth in § 1.53(f).

37 C.F.R. § 1.784(1).

NOTE: If the new application being transmitted is a divisional, continuation or a continuation-in-part of a parent case, or where the parent case is an International Application which designated the U.S., or benefit of a prior provisional application is claimed, then check the following item and complete and attach **ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED**.

WARNING: If an application claims the benefit of the filing date of an earlier filed application under 35 U.S.C. 120, 121 or 365(c), the 20-year term of that application will be based upon the filing date of the earliest U.S. application that the application makes reference to under 35 U.S.C. 120, 121 or 365(c). (35 U.S.C. 154(b)(2) does not take into account, for the determination of the patent term, any application on which priority is claimed under 35 U.S.C. 119, 365(a) or 365(b).) For a c-i-p application, applicant should review whether any claim in the patent that will issue is supported by an earlier application and, if not, the applicant should consider canceling the reference to the earlier filed application. The term of a patent is not based on a claim-by-claim approach. See Notice of April 14, 1995, 60 Fed. Reg. 20,195, at 20,205.

(Application Transmittal [4-1]—page 2 of 11)

00520110-030700

135
129

136
130

WARNING: When the last day of pendency of a provisional application falls on a Saturday, Sunday, or Federal holiday within the District of Columbia, any nonprovisional application claiming benefit of the provisional application must be filed prior to the Saturday, Sunday, or Federal holiday within the District of Columbia. See 37 C.F.R. § 1.78(a)(3).

- ☐ The new application being transmitted claims the benefit of prior U.S. application(s). Enclosed are ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

3. Papers Enclosed

A. Required for filing date under 37 C.F.R. § 1.53(b) (Regular) or 37 C.F.R. § 1.163 (Design) Application

14 Pages of specification
5 Pages of claims
2 Sheets of drawing

WARNING: DO NOT submit original drawings. A high quality copy of the drawings should be supplied when filing a patent application. The drawings that are submitted to the Office must be on strong, white, smooth, and non-shiny paper and meet the standards according to § 1.84. If corrections to the drawings are necessary, they should be made to the original drawing and a high-quality copy of the corrected original drawing then submitted to the Office. Only one copy is required or desired. For comments on proposed then-new 37 CFR 1.84, see Notice of March 8, 1988 (1990 O.G. 67-62).

NOTE: Identifying indicia, if provided, should include the application number or the title of the invention, inventor's name, docket number (if any), and the name and telephone number of a person to call if the Office is unable to match the drawings to the proper application. This information should be placed on the back of each sheet of drawing a minimum distance of 1.5 cm. (5/8 inch) down from the top of the page. 37 C.F.R. 1.84(c).

(complete the following, if applicable)

- ☐ The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)" 37 C.F.R. 1.84(b).
- ☐ formal
- ☒ informal

B. Other Papers Enclosed

___ Pages of declaration and power of attorney

1 Pages of abstract

___ Other

4. Additional papers enclosed

- ☐ Amendment to claims
- ☐ Cancel in this applications claims _____ before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
- ☐ Add the claims shown on the attached amendment. (Claims added have been numbered consecutively following the highest numbered original claims.)
- ☐ Preliminary Amendment
- ☐ Information Disclosure Statement (37 C.F.R. 1.86)
- ☐ Form PTO-1449 (PTO/SB/08A and 08B)
- ☐ Citations

(Application Transmittal [4-1]—page 3 of 11)

05520110-030700

- 137
131
- ☐ Declaration of Biological Deposit
 - ☐ Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence
 - ☐ Authorization of Attorney(s) to Accept and Follow Instructions from Representative
 - ☐ Special Comments
 - ☐ Other

5. Declaration or oath (including power of attorney)

NOTE: A newly executed declaration is not required in a continuation or divisional application provided that the prior nonprovisional application contained a declaration as required, the application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application (showing the signature or an indication thereon that it was signed) is submitted. The copy must be accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application was filed under § 1.47, then a copy of that declaration must be filed accompanied by a copy of the decision granting § 1.47 status or, if a nonsigning person under § 1.47 has subsequently joined in a prior application, then a copy of the subsequently executed declaration must be filed. See 37 C.F.R. §§ 1.63(d)(1)-(3).

NOTE: A declaration filed to complete an application must be executed, identify the specification to which it is directed, identify each inventor by full name including family name and at least one given name, without abbreviation together with any other given name or initial, and the residence, post office address and country or citizenship of each inventor, and state whether the inventor is a sole or joint inventor 37 C.F.R. § 1.63(d)(1)-(4).

- ☐ Enclosed
- Executed by

(check all applicable boxes)

- ☐ Inventor(s)
- ☐ legal representative of inventor(s).
37 CFR 1.42 or 1.43.
- ☐ joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached
 - ☐ This is the petition required by 37 CFR 1.47 and the statement required by 37 CFR 1.47 is also attached. See item 13 below for fee.

- ☒ Not Enclosed.

NOTE: Where the filing is a completion in the U.S. of an International Application or where the completion of the U.S. application contains subject matter in addition to the International Application, the application may be treated as a continuation or continuation-in-part, as the case may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION CLAIMED.

- ☐ Application is made by a person authorized under 37 C.F.R. 1.41(c) on behalf of all the above named inventor(s)

(The declaration or oath, along with the surcharge required by 37 CFR 1.16(e) can be filed subsequently).

- ☐ Showing that the filing is authorized.
(not required unless called into question. 37 CFR 1.41(d))

(Application Transmittal [4-1]—page 4 of 11)

00520110-030700

138
132

6. Inventorship Statement

WARNING: If the named inventors are each not the inventors of all the claims an explanation, including the ownership of the various claims at the time the last claimed invention was made, should be submitted.

The inventorship for all the claims in this application are:

☒ The same.

or

- ☐ Not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made,
- ☐ is submitted.
 - ☐ will be submitted.

7. Language

NOTE: An application including a signed oath or declaration may be filed in a language other than English. An English translation of the non-English language application and the processing fee of \$130.00 required by 37 CFR 1.174 is required to be filed with the application, or within such time as may be set by the Office. 37 CFR 1.62(d).

☒ English

☐ Non-English

- ☐ The attached translation includes a statement that the translation is accurate 37 C.F.R. 1.62(d).

8. Assignment

☒ An assignment of the invention to 401's

- ☐ is attached. A separate ☐ "COVER SHEET FOR ASSIGNMENT (DOCUMENT) ACCOMPANYING NEW PATENT APPLICATION" or ☐ FORM PTO 1595 is also attached.

☒ will follow.

NOTE: If an assignment is submitted with a new application, send two separate letters—one for the application and one for the assignment." Notice of May 4, 1990 (1114 O.G. 77-78).

WARNING: A newly executed "CERTIFICATE UNDER 37 CFR 3.73(b)" must be filed when a continuation-in-part application is filed by an assignee. Notice of April 30, 1993, 1180 O.G. 62-64.

(Application Transmittal [4-1]—page 6 of 11)

00520110.030700

129
1.33

9. Certified Copy

Certified copy(ies) of application(s)

Country	Appln. No.	Filed
Country	Appln. No.	Filed
Country	Appln. No.	Filed

from which priority is claimed

- ☐ is (are) attached
☐ will follow

NOTE: The foreign application forming the basis for the claim for priority must be referred to in the oath or declaration. 37 CFR 1.88(a) and 1.83.

NOTE: This item is for any foreign priority for which the application being filed directly relates. If any parent U.S. application or International Application from which this application claims benefit under 35 U.S.C. 120 is itself entitled to priority from a prior foreign application, then complete item 18 on the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

10. Fee Calculation (37 C.F.R. 1.16)

A. ☒ Regular application

CLAIMS AS FILED			
Number filed	Number Extra	Rate	Basic Fee 37 C.F.R. 1.16(a) ~~\$700.00~~ 600.00
Total Claims (37 CFR 1.16(c)) 20 =	—	x	\$ 22.00
Independent Claims (37 CFR 1.16(b)) 2 =	—	x	\$ 82.00
Multiple dependent claim(s), if any (37 CFR 1.16(d))		+	\$270.00

- ☐ Amendment cancelling extra claims is enclosed.
☐ Amendment deleting multiple-dependencies is enclosed.
☐ Fee for extra claims is not being paid at this time.

NOTE: If the fees for extra claims are not paid on filing they must be paid or the claims cancelled by amendment, prior to the expiration of the time period set for response by the Patent and Trademark Office in any notice of fee deficiency. 37 CFR 1.16(f).

Filing Fee Calculation

\$ 600.00

B. ☐ Design application
(\$330.00—37 CFR 1.16(f))

Filing Fee Calculation

\$ _____

C. ☐ Plant application
(\$540.00—37 CFR 1.16(g))

Filing fee calculation

\$ _____

(Application Transmitted (4-1)—page 6 of 11)

00520110.030700

198
134

11. Small Entity Statement(s)

- ☐ Statement(s) that this is a filing by a small entity under 37 CFR 1.9 and 1.27 is (are) attached

WARNING: "Status as a small entity must be specifically established in each application or patent in which the status is available and desired. Status as a small entity in one application or patent does not affect any other application or patent, including applications or patents which are directly or indirectly dependent upon the application or patent in which the status has been established. The refiling of an application under § 1.53 as a continuation, division, or continuation-in-part (including a continued prosecution application under § 1.53(d)), or the filing of a reissue application requires a new determination as to continued entitlement to small entity status for the continuing or reissue application. A nonprovisional application claiming benefit under 35 U.S.C. 119(a), 120, 121, or 365(c) of a prior application, or a reissue application may rely on a statement filed in the prior application or in the patent if the nonprovisional application or the reissue application includes a reference to the statement in the prior application or in the patent or includes a copy of the statement in the prior application or in the patent and status as a small entity is still proper and desired. The payment of the small entity basic statutory filing fee will be treated as such a reference for purposes of this section." 37 C.F.R. § 1.28(a)(2).

(complete the following, if applicable)

- ☒ Status as a small entity was claimed in prior application 09, 340,227, filed on 7 May 98, from which benefit is being claimed for this application under

35 U.S.C. ☐ 119(a),
☒ 120,
☒ 121,
☐ 365(c),

and which status as a small entity is still proper and desired

- ☐ A copy of the statement in the prior application is included

Filing Fee Calculation (50% of A, B or C above)

\$ 325

NOTE: Any excess of the full fee paid will be refunded if small entity status is established and a refund request are filed within 2 months of the date of timely payment of a full fee. The two-month period is not extendable under § 1.136, 37 CFR 1.28(f).

12. Request for International-Type Search (37 C.F.R. 1.104(d))

(complete, if applicable)

- ☐ Please prepare an international-type search report for this application at the time when national examination on the merits takes place.

(Application Transmittal (4-1)—page 7 of 11)

00520110-030700

141
135

13. Fee Payment Being Made at This Time

☒ Not Enclosed

☒ No filing fee is to be paid at this time.
(This and the surcharge required by 37 C.F.R. 1.16(e) can be paid subsequently.)

☐ Enclosed

☐ Filing fee

\$ _____

☐ Recording assignment

(\$40.00; 37 C.F.R. 1.21(h))

(See attached "COVER SHEET FOR
ASSIGNMENT ACCOMPANYING NEW
APPLICATION".)

\$ _____

☐ Petition fee for filing by other than all the
inventors or person on behalf of the inventor
where inventor refused to sign or cannot be
reached

(\$130.00; 37 C.F.R. 1.47 and 1.17(i))

\$ _____

☐ For processing an application with a
specification in

a non-English language

(\$130.00; 37 C.F.R. 1.52(d) and 1.17(d))

\$ _____

☐ Processing and retention fee

(\$130.00; 37 C.F.R. 1.53(d) and 1.21(i))

\$ _____

☐ Fee for international-type search report

(\$40.00; 37 C.F.R. 1.21(e))

\$ _____

NOTE: 37 CFR 1.21(f) establishes a fee for processing and retaining any application that is abandoned for failing to complete the application pursuant to 37 CFR 1.53(f) and this, as well as the charges to 37 CFR 1.53 and 1.78(b)(1), indicate that in order to obtain the benefit of a prior U.S. application, either the basic filing fee must be paid, or the processing and retention fee of § 1.21(f) must be paid, within 1 year from notification under § 53(f).

Total fees enclosed

\$ _____

14. Method of Payment of Fees

☐ Check in the amount of \$ _____

☐ Charge Account No _____ In the amount of
\$ _____

A duplicate of this transmittal is attached

NOTE: Fees should be itemized in such a manner that it is clear for which purpose the fees are paid. 37 CFR 1.22(b).

(Application Transmittal [4-1]—page 8 of 11)

03520110-030700

142
136

15. Authorization to Charge Additional Fees

WARNING: If no fees are to be paid on filing, the following items should not be completed.

WARNING: Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges. If extra claim charges are authorized.

- ☐ The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. _____.

☐ 37 C.F.R. 1.16(a), (f) or (g) (filing fees)

☐ 37 C.F.R. 1.16(b), (c) and (d) (presentation of extra claims)

NOTE: Because additional fees for excess or multiple dependent claims not paid on filing or on later presentation must only be paid or these claims cancelled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 CFR 1.16(g)), it might be best not to authorize the PTO to charge additional claim fees, except possibly when dealing with amendments after final action.

☐ 37 C.F.R. 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)

☐ 37 C.F.R. §§ 1.17(a)(1)-(5) (extension fees pursuant to § 1.136(a)).

☐ 37 C.F.R. 1.17 (application processing fees)

NOTE: "A written request may be submitted in an application that is an authorization to treat any concurrent or future reply, requiring a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. An authorization to charge all required fees, fees under § 1.17 or all required extension of time fees will be treated as a constructive petition for an extension of time in any concurrent or future reply requiring a petition for an extension of time under this paragraph for its timely submission. Submission of the fee set forth in § 1.17(b) will also be treated as a constructive petition for an extension of time in any concurrent reply requiring a petition for an extension of time under this paragraph for its timely submission." 37 C.F.R. § 1.136(a)(3).

☐ 37 C.F.R. 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. 1.311(b))

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance. 37 CFR 1.311(b).

NOTE: 37 CFR 1.289 requires "Notification of any change in status resulting in loss of entitlement to small entity status must be filed in the application . . . prior to paying, or at the time of paying, the issue fee. . . ." From the wording of 37 CFR 1.289, (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.

(Application Transmittal [4-1]—page 9 of 11)

00520110.030700

143
137

16. Instructions as to Overpayment

NOTE - Amounts of twenty-five dollars or less will not be returned unless specifically requested within a reasonable time, nor will the payer be notified of such amounts; amounts over twenty-five dollars may be returned by check or, if requested, by credit to a deposit account." 37 C.F.R. § 1.204.

☐ Credit Account No. _____

☒ Refund

00520110-030700

Reg. No 27056

Tel No. (B) 526-8000

Customer No.



SIGNATURE OF PRACTITIONER

Donald N. Helgen

(type or print name of attorney)

35 Central St

P.O. Address

Manchester MA 01944

(Application Transmittal [4-1]—page 10 of 11)

T94
138

8

Incorporation by reference of added pages

(check the following item if the application in this transmittal claims the benefit of prior U.S. application(s) (including an international application entering the U.S. stage as a continuation, divisional or C-I-P application) and complete and attach the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED)

8

Plus Added Pages for New Application Transmittal Where Benefit of Prior U.S. Application(s) Claimed

Number of pages added 5

☐ **Plus Added Pages for Papers Referred to in Item 4 Above**

Number of pages added _____

☐ **Plus added pages deleting names of inventor(s) named in prior application(s) who is/are no longer inventor(s) of the subject matter claimed in this application.**

Number of pages added _____

☐ **Plus "Assignment Cover Letter Accompanying New Application"**

Number of pages added _____

☐ **Statement Where No Further Pages Added**

(if no further pages form a part of this Transmittal, then end this Transmittal with this page and check the following item)

☐ **This transmittal ends with this page.**

00520110.030700

Practitioner's Docket No.

Thompson-4

PATENT

145
139

**ADDED PAGES FOR APPLICATION TRANSMITTAL WHERE BENEFIT OF
PRIOR U.S. APPLICATION(S) CLAIMED**

NOTE: See 37 C.F.R. § 1.78.

17. Relate Back

WARNING: If an application claims the benefit of the filing date of an earlier filed application under 35 U.S.C. §§ 120, 121 or 365(c), the 20-year term of that application will be based upon the filing date of the earliest U.S. application that the application makes reference to under 35 U.S.C. §§ 120, 121 or 365(c). (35 U.S.C. § 154(b)(2) does not take into account, for the determination of the patent term, any application on which priority is claimed under 35 U.S.C. §§ 119, 365(a) or 365(c).) For a c-i-p application, applicant should review whether any claim in the patent that will issue is supported by an earlier application and, if not, the applicant should consider canceling the reference to the earlier filed application. The term of a patent is not based on a claim-by-claim approach. See Notice of April 14, 1995, 60 Fed. Reg. 20,195, at 20,205.

(complete the following, if applicable)

- ☒ Amend the specification by inserting, before the first line, the following sentence:
A. 35 U.S.C. § 119(a)

NOTE: "Any nonprovisional application claiming the benefit of one or more prior filed expending provisional applications must contain or be amended to contain in the first sentence of the specification following the title a reference to each such prior provisional application, identifying it as a provisional application, and including the provisional application number (consisting of serial code and serial number)." 37 C.F.R. § 1.78(b)(4).

- ☐ "This application claims the benefit of U.S. Provisional Application(s) No(s).:

APPLICATION NO(S):

FILING DATE

_____/_____
_____/_____
_____/_____

(Added Pages for Application Transmittal Where Benefit of Prior U.S. Application(s) Claimed
[4-1.1]—page 1 of 8)

03520110-030700

196
140

B. 35 U.S.C. §§ 120, 121 and 365(c)

NOTE: "Except for a continued prosecution application filed under § 1.534, any nonprovisional application claiming the benefit of one or more prior filed copending nonprovisional applications or international applications designating the United States of America must contain or be amended to contain in the first sentence of the specification following the title a reference to each such prior application, identifying it by application number (consisting of the series code and serial number) or international application number and international filing date and indicating the relationship of the applications. Cross-references to other related applications may be made when appropriate." (See § 1.14(d), 37 C.F.R. § 1.78(b)(2).

- ☒ "This application is a
☐ continuation
☒ continuation-in-part
☐ divisional

of copending application(s)

- ☐ application number of 1,340,227 filed on 7 July
☐ International Application _____ filed on _____
_____ and which designated the U.S."

NOTE: The proper reference to a prior filed PCT application that entered the U.S. national phase is the U.S. serial number and the filing date of the PCT application that designated the U.S.

NOTE: (1) Where the application being transmitted adds subject matter to the International Application, then the filing can be as a continuation-in-part or (2) if it is desired to do so for other reasons than the filing can be as a continuation.

NOTE: The deadline for entering the national phase in the U.S. for an international application was clarified in the Notice of April 28, 1987 (1079 O.G. 32 to 46) as follows:

"The Patent and Trademark Office considers the international application to be pending until the 22nd month from the priority date if the United States has been designated and no Demand for International Preliminary Examination has been filed prior to the expiration of the 19th month from the priority date and until the 32nd month from the priority date if a Demand for International Preliminary Examination which elected the United States of America has been filed prior to the expiration of the 19th month from the priority date, provided that a copy of the international application has been communicated to the Patent and Trademark Office within the 20 or 30 month period respectively. If a copy of the international application has not been communicated to the Patent and Trademark Office within the 20 or 30 month period respectively, the international application becomes abandoned as to the United States 20 or 30 months from the priority date respectively. These periods have been placed in the rules as paragraph (f) of § 1.494 and paragraph (f) of § 1.495. A continuing application under 35 U.S.C. 365(c) and 120 may be filed anytime during the pendency of the international application."

- ☐ "The nonprovisional application designated above, namely application _____ / _____, filed _____, claims the benefit of U.S. Provisional Application(s) No(s) ..

APPLICATION NO(S):

FILING DATE

_____ / _____	_____ "
_____ / _____	_____ "
_____ / _____	_____ "

- ☐ Where more than one reference is made above, please combine all references into one sentence.

03520110-030700

199
141

18. Relate Back—35 U.S.C. § 119 Priority Claim for Prior Application

The prior U.S. application(s), including any prior international Application designating the U.S., identified above in item 17B, in turn itself claim(s) foreign priority(ies) as follows:

Country	Appl. no.	Filed on
---------	-----------	----------

The certified copy(ies) has (have)

- ☐ been filed on _____, in prior application 0 / _____, which was filed on _____
- ☐ is (are) attached

WARNING: The certified copy of the priority application that may have been communicated to the PTO by the International Bureau may not be relied on without any need to file a certified copy of the priority application in the continuing application. This is so because the certified copy of the priority application communicated by the International Bureau is placed in a folder and is not assigned a U.S. serial number unless the national stage is entered. Such folders are disposed of if the national stage is not entered. Therefore, such certified copies may not be available if needed later in the prosecution of a continuing application. An alternative would be to physically remove the priority documents from the folders and transfer them to the continuing application. The resources required to request transfer, retrieve the folders, make suitable record notations, transfer the certified copies, enter and make a record of such copies in the Continuing Application are substantial. Accordingly, the priority documents in folders of international applications that have not entered the national stage may not be relied on. Notice of April 22, 1987 (1079 O.G. 32 to 43).

19. Maintenance of Dependency of Prior Application

NOTE: The PTO finds it useful if a copy of the petition filed in the prior application extending the term for response is filed with the papers constituting the filing of the continuation application. Notice of November 6, 1985 (1080 O.G. 27).

- A. ☐ Extension of time in prior application

(This item must be completed and the papers filed in the prior application, if the period set in the prior application has run.)

- ☐ A petition, fee and response extends the term in the pending prior application until _____
- ☐ A copy of the petition filed in prior application is attached.

- B. ☐ Conditional Petition for Extension of Time in Prior Application

(complete this item, if previous item not applicable)

- ☐ A conditional petition for extension of time is being filed in the pending prior application.
- ☐ A copy of the conditional petition filed in the prior application is attached.

00520110.030700

148
142

20. Further Inventorship Statement Where Benefit of Prior Application(s) Claimed

(complete applicable item (a), (b) and/or (c) below)

- (a) ☐ This application discloses and claims only subject matter disclosed in the prior application whose particulars are set out above and the inventor(s) in this application are

☐ the same.

☐ less than those named in the prior application. It is requested that the following inventor(s) identified for the prior application be deleted:

(type name(s) of inventor(s) to be deleted)

- (b) ☒ This application discloses and claims additional disclosure by amendment and a new declaration or oath-is-being filed. With respect to the prior application, the inventor(s) in this application are will be

☒ the same.

☐ the following additional inventor(s) have been added:

(type name(s) of inventor(s) to be added)

- (c) The inventorship for all the claims in this application are

☒ the same.

☐ not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made

☐ is submitted.

☐ will be submitted.

00520110.030700

149
143**21. Abandonment of Prior Application (if applicable)**

- ☐ Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application coexisting with said prior application.

NOTE: According to the Notice of May 13, 1983 (103, TMOG 6-7), the filing of a continuation or continuation-in-part application is a proper response with respect to a petition for extension of time or a petition to revive and should include the express abandonment of the prior application conditioned upon the granting of the petition and the granting of a filing date to the continuing application.

22. Petition for Suspension of Prosecution for the Time Necessary to File an Amendment

WARNING: "The claims of a new application may be finally rejected in the first Office action in those situations where (A) the new application is a continuing application of, or a substitute for, an earlier application, and (B) all the claims of the new application (1) are drawn to the same invention claimed in the earlier application, and (2) would have been properly finally rejected on the grounds of art of record in the next Office action if they had been entered in the earlier application." M.P.E.P., § 708.07(b), 7th ed.

NOTE: Where it is possible that the claims on file will give rise to a first action final for this continuation application and for some reason an amendment cannot be filed promptly (e.g., experimental data is being gathered) it may be desirable to file a petition for suspension of prosecution for the time necessary."

(check the next item, if applicable)

- ☐ There is provided herewith a Petition To Suspend Prosecution for the Time Necessary to File An Amendment (New Application Filed Concurrently)

23. Small Entity (37 C.F.R. § 1.28(a))

- ☒ Applicant has established small entity status by the filing of a statement in parent application of 1,342,777 on 7-2-84.
- ☐ A copy of the statement previously filed is included.

WARNING: See 37 C.F.R. § 1.28(b).

WARNING: "Small entity status must not be established when the person or persons signing the . . . statement can unequivocally make the required self-certification." M.P.E.P., § 608.03, 7th ed. (emphasis added).

24. NOTIFICATION IN PARENT APPLICATION OF THIS FILING

- ☐ A notification of the filing of this (check one of the following)
- ☐ continuation
 - ☐ continuation-in-part
 - ☐ divisional

is being filed in the parent application, from which this application claims priority under 35 U.S.C. § 120.

(Added Pages for Application Transmitted Where Benefit of Prior U.S. Application(s) Claimed
[4-1.1]-page 5 of 8)

00520410-030700

**Expanded Clitoral Sensitizing Compounds with Methods and
Apparatus for the Delivery of these Compounds**

Background of the Invention

Field of the Invention

This invention relates to arrangements for the stimulation of females and more particularly to topical application of specialized stimulatory medicaments, and is a continuation-in part application of my earlier co-pending application serial number 09/469,959 filed 22 Dec 1999, which is a continuation-in-part application of co-pending application serial number 09/414,250 filed 7 Oct 1999 which is a continuation-in-part application of co-pending application serial number 09/340,227 filed 7 July 1999, each of which are incorporated herein by reference in their entirety .

Prior art

The unique properties of the clitoral sensitizing compounds described in my earlier co-pending patent application 09/469,959 encompasses the vasodilatation of clitoral blood vessels by the initial effect of menthol to facilitate and promote the absorption of L-arginine when topically applied to

+31
145

the mucous membrane of the clitoris. The L-arginine stimulates the nitric oxide synthase mediated production of nitric oxide to effect clitoral sensitivity, arousal, and erection by sustained vasodilatation. Both of these actions are specific to the topical application of the compound to the mucous membrane of the clitoris and presume an inert, non-active base or vehicle. In the menthol/L-arginine compound, the menthol actually acts as a vehicle to enhance the absorption of L-arginine.

Brief Summary of the Invention

The present invention relates to alternate preparations of menthol and related cooling compounds that comprises a class of single-source of botanical or essential oils that can be used individually or as a combination of several oils such as: Peppermint oil; Cornmint oil; Eucalyptus oil; Citronella oil; Indian turpentine oil; Camphor oil and Cinnamon oil.

In fact, all of the botanicals listed by Steinberg in "Frequency Use of Botanicals," in *Cosmetics and Toiletries* magazine, Volume 113, October, 1998, (incorporated herein by reference) are members of this class of single-source botanical or essential oils. Potentially, any of these referenced oils could evoke the menthol-like effect on the mucous membrane to facilitate or

00520110-030700

132
146

promote the topical absorption of L-arginine. In addition, known minor skin irritants can cause a profound reaction when topically applied to mucous membrane, such as redness, irritation, and reflex vasodilatation. This irritant reaction associated with vasodilatation shares some similarities with the menthol effect, and could quite effectively substitute for the menthol in promoting L-arginine absorption and actions. Salicylate and capsiatin are two of the commonly used minor skin irritants. Oil soluble vitamins (co-enzymes) A, D, or E, could also potentiate absorption of menthol, L-arginine, minor skin irritants, or any of the menthol-related cooling compounds. The oil soluble vitamins could be used to substitute for, or be used in addition to, any of the previously listed components in a topical clitoral sensitizing preparation.

The invention may further comprise alternate preparations for the base or the vehicle. Such biologically active agents (menthol or its substitutes) and L-arginine can be compounded in a non-biologically active base, or in a biologically active base that promotes absorption, a vehicle. Any base or vehicle is intended to liquefy at body heat and in the presence of moisture present in mucous membrane when topically applied to mucous membrane tissue. Campos and Eccleston is "Vitamin A Skin Penetration, " *Cosmetics*

00520110-030700

13
147

and *Toilettries* magazine, volume 113, July, 1998, describe and quantify how different vehicles influence and promote the hairy skin (keratinized stratified squamous epithelium) absorption of Vitamin A. Mucous membranes absorb solutions more readily than hairy skin, but display linear absorption potentials relative to the vehicles studies by Campos and Eccleston. An active vehicle may be engineered that synergistically functions to promote the absorption and actions of menthol, menthol-related compounds, biologically derived oils, minor skin irritants, oil soluble vitamins, L-arginine, or any combination of these.

There are solid/liquid state dynamics for the topical delivery of clitoral sensitizing compounds which cover any of the potential compounds for topical application to sensitize the clitoris because they can have different solid/liquid states at ambient and at body temperatures. A solid compound, such as exemplified by the Chap Stick® Lip Balm, A. H. Robbins Company, of Richmond, Virginia, could be directly applied to the undercarriage of the clitoris, and liquefy at body temperature and in the moisture inherent in mucous membrane tissue. Liquefied compounds are readily absorbed, dependent on various other factors described. A gel/cream or liquid compound could be directly applied to the clitoris for topical

00520110.030700

129
148

absorption. Like the solid-state compound, the gel/cream must liquefy before absorption can be effected. The dynamics of how rapidly a compound transforms from a solid state or gel/cream state to a liquid state could be controlled to evoke an almost immediate effect, or a relatively delayed effect, before absorption of the compound.

A crystalline related dissolution may be different from the temperature related dissolution of a solid or a gel/cream. Small crystals of menthol, L-arginine, or any of the previously described components, may be suspended in a base vehicle. Their availability for absorption would depend on their dissolution from a crystalline state to a liquid state. The crystalline effect may be designed to control the rate of absorption: for instance, whether the compound were available for absorption immediately on application, or if a delayed, sustained absorption over a period of time were desired. Both of these parameters could allow the discrete, private application of the clitoral-sensitizing compound in anticipation of intercourse, without knowledge of the partner.

Because the clitoral-sensitizing compounds are also intended to function independently without the preferred intercourse-related physical

00520110.030700

135

149

stimulation of the clitoris as taught in my aforementioned patent application serial numbers 09/414,250, 09/340,227 and 09/469,959, the menthol/L-arginine compounds may also be arranged to be available in various strength to address the needs of all women. The menthol may be compounded in multiple strengths, ranging from 0.1% to 5%, and any increment in between. The L-arginine may also be compounded in multiple strengths ranging from 1% to 10%. The spectrum of different strengths may be compounded into a single delivery system, such as lip balm, or alternatively, in all of the potential delivery systems: solid, gel/cream, and liquid.

A single use or a multiple use delivery systems comprising clitoral-sensitizing preparations may be individually packaged within a small tube or packet for single use. Conversely, a multiple-dose reusable delivery system, like a tube of hand cream or toothpaste, or a stick of lip balm, may be packaged for personal use.

The apparatus and methods to deliver a topical preparation to the clitoris may be comprised of a solid or semi-solid compound that may be directly applied to the undercarriage of the clitoris regardless of the use of a single-or multiple-use delivery system. The clitoral contact area of the solid

00520110-030700

156
150

or semi-solid compound in one preferred embodiment will have a notch to increase the surface area and clitoral contact of the compound. The notch is arranged with a height of 0.5 to 2 centimeters, and a maximum width of 2 centimeters at the rim of the notch. A properly designed concave notch will topically apply the compound to the 180 degree undercarriage of the clitoris. With proper directions for use, the application surface will initially contact the vestibular tissue at the base of the clitoris, to spread the compound on the entire clitoris.

A gel/cream or liquid compound would be applied to the clitoris with the same motions, but would require a different type of application device. The gel/cream or liquid could be applied by "roller balls" like those used to apply viscous deodorants, by a sponge-type applicator, or by a brush type of system. Any of the delivery devices for gel/cream or liquids could be designed to increase the surface area of the applicator tip and generally use the concave notch described for the solid compounds. The gel/cream and liquid applicators would have either a single-use reservoir or a multi-use reservoir. All of the delivery devices would have a cap that would seal the device before the initial use, and protect the applicator tip from contamination before use. Multi-use devices would have a resealing cap.

00520110-030700

157
151

The invention thus comprises a hand-manipulable, clitoral stimulant-applying applicator for use to apply a clitoral stimulating compound to the clitoral area of the human female, comprising: a reservoir for containment of a clitoral stimulating compound, a clitoral stimulating compound in said reservoir; and a removable cover on the reservoir to expose the compound to permit said compound to be applied topically. The cover may comprise a removable cap. The reservoir may comprise a tube and said cover. The compound may comprise a gel. The compound may comprise a cream. The compound may comprise a fluid liquid. The compound may comprise a semi-solid. The semi-solid compound may have a notch on its distalmost end to facilitate the application of the compound. The applicator may include a brush thereon. The applicator may include a sponge thereon. The applicator may include a roller ball arrangement thereon. The compound may be comprised of a mixture of menthol and L-arginine. The compound may have components selected from the group consisting of: Peppermint oil, Cornmint oil, Eucalyptus oil, Citronella oil, Indian turpentine oil, Camphor oil and Cinnamon oils. The compound may have components selected from the group consisting of: Salicylate, capsiatin, and oil soluble vitamins (co-enzymes) of A, D, or E.

00520110-030700

138
152

The invention also includes a method of sensitizing the clitoris of a human female, comprising the steps of: applying a compound of sensitizing agent to the clitoris; and selecting a component of said sensitizing agent from the group consisting of: Peppermint oil, Cornmint oil, Eucalyptus oil, Citronella oil, Indian turpentine oil, Camphor oil, Cinnamon oils, Salicylate, capsiatin, and oil soluble vitamins (co-enzymes) of A, D, or E. The steps may include placing the sensitizing agent in a reservoir of an applicator; arranging a cover on the applicator to protect the agent in the reservoir. The applicator may include a brush. The applicator may include a roller at one end thereof. The applicator may include a sponge at one end thereof. The sensitizing agent comprises a semi-solid stick having a "V" notch on a distal end thereof to facilitate application of the agent to a clitoris.

Brief Description of the Drawings

The objects and advantages of the present invention will become more apparent when viewed in conjunction with the following drawings in which:

Figure 1 is a front elevational view of a solid compound single-use applicator;

Figure 2 is a view taken along the lines 2-2 of figure 1;

00520110-030700

159
153

Figure 3 is a front elevational view of a solid compound multiple-use applicator;

Figure 4 is a view taken along the lines 4-4 of figure 3;

Figure 5 is a front elevational view of a gel/cream/liquid compound single-use applicator;

Figure 6 is a front elevational view of a gel/cream/liquid compound single or multiple use brush applicator;

Figure 7 is a view of the applicator shown in figure 6, with its cap off;

Figure 8 is a side elevational view, in section, of the applicator cap shown in figure 6;

Figure 9 is front elevational view of a gel/cream or liquid applicator with roller balls; and

Figure 10 is a view taken along the lines 10-10 of figure 9.

Description of Preferred Embodiments

Referring now to the invention and the drawings in detail, alternate preparations of menthol and related cooling compounds comprises a class of single-source of botanical or essential oils that can be used individually or as a combination of several oils such as: Peppermint oil; Commint oil;

00520110.030700

A60
154

Bucalyptus oil; Citronella oil, Indian turpentine oil, Camphor oil and Cinnamon oils, as compounds of the present invention. Any of these referenced oils could evoke the menthol-like effect on the mucous membrane to facilitate or promote the topical absorption of L-arginine. Salicylate and capsiatin, two commonly used minor skin irritants and oil soluble vitamins (co-enzymes) A, D, or E, could also potentiate absorption of menthol, L-arginine, minor skin irritants, or any of the menthol-related cooling compounds. The oil soluble vitamins could be used to substitute for, or be used in addition to, any of the previously listed components in a topical clitoral sensitizing preparation. Such solid/liquid state dynamics for the topical delivery of clitoral sensitizing compounds which cover any of the potential compounds for topical application to sensitize the clitoris because they can have different solid/liquid states at ambient and at body temperatures.

A gel/cream or liquid compound could be directly applied to the clitoris for topical absorption. Like the solid-state compound, the gel/cream must liquefy before absorption can be effected. The dynamics of how rapidly a compound transforms from a solid state or gel/cream state to a

09520110-030700

151
155

liquid state could be controlled to evoke an almost immediate effect, or a relatively delayed effect, before absorption of the compound.

A crystalline related dissolution may be different from the temperature related dissolution of a solid or a gel/cream. Small crystals of menthol, L-arginine, or any of the previously described components, may be suspended in a base vehicle. Their availability for absorption would depend on their dissolution from a crystalline state to a liquid state. The crystalline effect may be designed to control the rate of absorption: for instance, whether the compound were available for absorption immediately on application, or if a delayed, sustained absorption over a period of time were desired. Both of these parameters could allow the discrete, private application of the clitoral-sensitizing compound in anticipation of intercourse, without knowledge of the partner.

A single use or a multiple use delivery systems comprising a clitoral-sensitizing preparation 10 may be individually packaged within a small tube 12 or packet 14 for single use, as shown in figures 1, 2 and 5. The tube 12 may be gripped by the thumb and first finger, and the compound preparation thereon applied as desired.

00520110-030700

162
156

The packet 14 shown in figure 5 has a break-away seal 15 which permits the gel/cream or liquid 10 therein to be readily applied by merely squeezing the packet 14. Conversely, a multiple-dose reusable delivery system, like a tube of hand cream or toothpaste, or a stick of semi-solid compound, clitoral-sensitizing balm 16, may be packaged for personal use, as shown by the "lipstick-like" rotatively adjustable applicators 18 in figures 3 and 4. This adjustable-applicator 18 has a cap 20 to cover the balm compound 16.

The apparatus and methods to deliver a topical preparation to the clitoris may also be comprised of a solid or semi-solid compound that may be directly applied to the undercarriage of the clitoris regardless of the use of a single-or multiple-use delivery system. The clitoral contact area of the solid or semi-solid compound in one preferred embodiment will have a notch "V" to increase the surface area and clitoral contact of the compound 16, as shown in figures 1 and 3. The notch "V" is arranged with a height of 0.5 to 2 centimeters, and a maximum width of 2 centimeters at the rim of the notch "V". A properly designed concave notch "V" will topically apply the compound 16 to the 180 degree undercarriage of the clitoris. With proper directions for use, the application surface will initially contact the vestibular

00520110-030700

153
157

tissue at the base of the clitoris, to spread the compound on the entire clitoris. A gel/cream or liquid compound 30 of the present invention would be applied to the clitoris with the same motions, but would require a different type of application device. The gel/cream or liquid compound 30 may be applied by "roller balls" 32 like those used to apply viscous deodorants, as shown in figures 9 and 10, supported within a foraminous top 34, covered when not needed, by a cap 46. The gel/cream or liquid compound 30 may also be applied by a sponge or brush 40 secured to a top 42 in a reservoir 44, as shown in figures 6 and 7. A cap 48, shown also in figure 8 may include a removable seal 50, both of which are arranged to be removable to expose the sponge or brush 40 and openings 46 in the reservoir 44 to supply the fluid compound thereto. Any of the delivery devices for gel/cream or liquids could be designed to increase the surface area of the applicator tip and generally use the concave notch described for the solid compounds. The gel/cream and liquid applicators would have either a single-use reservoir or a multi-use reservoir. All of the delivery devices would have a cap "C" that would seal the device before the initial use, and protect the applicator tip from contamination before use. Multi-use devices, such as shown in figures 3, 4, 6, 7 and 9 would have the resealing cap 48 for their protection

00520110-030700

164
158

I claim:

1. A hand-manipulable, clitoral stimulant-applying applicator for use to apply a clitoral stimulating compound to the clitoral area of the human female, comprising:
 - a reservoir for containment of a clitoral stimulating compound;
 - a clitoral stimulating compound in said reservoir; and
 - a removable cover on said reservoir to expose said compound to permit said compound to be applied topically.
2. The hand-manipulable, clitoral stimulant-applying applicator as recited in claim 1, wherein said cover comprises a removable cap.
3. The hand-manipulable, clitoral stimulant-applying applicator as recited in claim 1, wherein said reservoir comprises a tube and said cover.
4. The hand-manipulable, clitoral stimulant-applying applicator as recited in claim 1, wherein said compound comprises a gel.

00520110-030700

165
159

5. The hand-manipulable, clitoral stimulant-applying applicator as recited in claim 1, wherein said compound comprises a cream.
6. The hand-manipulable, clitoral stimulant-applying applicator as recited in claim 1, wherein said compound comprises a fluid liquid.
7. The hand-manipulable, clitoral stimulant-applying applicator as recited in claim 1, wherein said compound comprises a semi-solid.
8. The hand-manipulable, clitoral stimulant-applying applicator as recited in claim 7, wherein said semi-solid compound has a notch on its distalmost end to facilitate the application of said compound.
9. The hand-manipulable, clitoral stimulant-applying applicator as recited in claim 6, wherein said applicator includes a brush thereon.
10. The hand-manipulable, clitoral stimulant-applying applicator as recited in claim 6, wherein said applicator includes a sponge thereon.

00520140.030700

166
160

11. The hand-manipulable, clitoral stimulant-applying applicator as recited in claim 6, wherein said applicator includes a roller ball arrangement thereon.
12. The hand-manipulable, clitoral stimulant-applying applicator as recited in claim 1, wherein said compound comprises a mixture of menthol and L-arginine.
13. The hand-manipulable, clitoral stimulant-applying applicator as recited in claim 1, wherein said compound has components selected from the group consisting of: Peppermint oil, Cornmint oil, Eucalyptus oil, Citronella oil, Indian turpentine oil, Camphor oil and Cinnamon oils
14. The hand-manipulable, clitoral stimulant-applying applicator as recited in claim 1, wherein said compound has components selected from the group consisting of: Salicylate, capsiatin, and oil soluble vitamins (co-enzymes) of A, D, or E.

00520110-030700

167
161

15. A method of sensitizing the clitoris of a human female, comprising the steps of:

applying a compound of sensitizing agent to said clitoris; and
selecting a component of said sensitizing agent from the group consisting of: Peppermint oil, Cornmint oil, Eucalyptus oil, Citronella oil, Indian turpentine oil, Camphor oil, Cinnamon oils, Salicylate, capsiatin, and oil soluble vitamins (co-enzymes) of A, D, or E.

16. The method of sensitizing the clitoris of a human female as recited in claim 15, comprising the steps of:

placing said sensitizing agent in a reservoir of an applicator;
arranging a cover on said applicator to protect said agent in said reservoir.

17. The method of sensitizing the clitoris of a human female as recited in claim 15, wherein said applicator includes a brush.

18. The method of sensitizing the clitoris of a human female as recited in claim 15, wherein said applicator includes a roller at one end thereof.

168
162

19. The method of sensitizing the clitoris of a human female as recited in claim 15, wherein said applicator includes a sponge at one end thereof.
20. The method of sensitizing the clitoris of a human female as recited in claim 15, wherein said sensitizing agent comprises a semi-solid stick having a "V" notch on a distal end thereof to facilitate application of said agent to a clitoris.







00520110.0307 0

169
163





Abstract of the Disclosure

The present invention comprises a method and apparatus such as a hand-manipulable, clitoral stimulant-applying applicator for use to apply a clitoral stimulating compound to the clitoral area of the human female. A reservoir in the apparatus is arranged for containment of a clitoral stimulating compound, with a clitoral stimulating compound in said reservoir. A removable cover is arranged on the reservoir to expose the compound to permit the compound to be applied topically.

00520110.030700



09520110.030700



09520110.030700